

## FORM 1B:

### DOCUMENTATION OF ELIGIBILITY



### **TOLSURF**

E1RDM Randomization Date: Time: AE1CNAM 1B.1. Center Name: AE1RANDN2 1B.2. Randomization number: 1B.3. Date and time of birth: O No 1B.4. Has a sibling(s) been enrolled in this study? O Yes AE1SEN 1B.4.a. Enter Randomization #(s): 1B.5. INCLUSION CRITERIA REVIEW: **AE1GAW** AE1GAD 1B.5.a. Gestational Age: weeks: days: 1B.5.a.i. How was GA determined? (select one) AE1GAHD 0 O US < 20 wks 1 O Dates 2 O Physical Exam **AE1GA** 1B.5.a.ii. Is gestational age ≤ 28 weeks? O Yes O No **AE1IAGED AE1IAGE** 1B.5.b. Age in days: (DOB = Day 1)O Yes 1B.5.b.i. Is infant between 7-14 days of life? <u>Ω</u> No

1B.5.e. Are any of the 4 Inclusion Criteria listed above answered "No"?

1B.5.c. Intubated and mechanically ventilated between 7 - 14 days of life?

1B.5.d. Plan to treat with Inhaled Nitric Oxide if enrolled in TOLSURF?

1 Yes 0-Complete Form 19 - Protocol Violations, Q19.2.a. **AE1IPRVIO** 0 No O

Continue to page 2 and answer all questions.

AE1INT7T14

1<sub>O Yes</sub> 5 No AE1PLTRINC

O<sub>No</sub>

O Yes



## **TOLSURF**

## FORM 1B: DOCUMENTATION OF ELIGIBILITY

Screening ID #	Secondary ID	Staff Initials	Randomization #
AE2ID A	E2ACRO	STFI	P AE2RANDN

1B.6. E	XCLUSION CRITERIA REVIEW:		
1B.6.a.	Infant has serious congenital malformations or chromosomal abnormalities? (see MOP)  AE2SCMCA	d Yes	<mark>0</mark> No
1B.6.b.	Is life expectancy < 7 days, starting at DOL 7?	1 O Yes	O O No
1B.6.c.	Infant is clinically unstable (See MOP)	1 O Yes	O O No
1B.6.d.	QUESTION REMOVED 11/7/12		_
1B.6.e.	Treated with surfactant within the 48 hours prior to enrollment.	O Yes	O No
1B.6.f.	Unlikely to be able to collect primary endpoint data at 36 weeks.	1 O Yes	<b>0</b> O No

1B.6.g. Are any of the 6 Exclusion Criteria listed above answered "Yes"?


1Yes Complete Form 19 - Protocol Violations, Q19.2.1 E2EPRVIO

No C

1B.7. CONSENT and HIPAA FORMS REVIEW:	
1B.7.a. Have Consent and HIPAA forms been signed and dated?	
1B.7.b. Date signed:   /   /   /   /   /   /   /   /   /	AE2CONSIGE
Complete Form 19 - Protocol Violations, Q19.2.c.	
Review signed ICF before answering questions below:	4
1B.7.c. Was parental permission obtained for banking samples?	O Yes O No
1B.7.d. Was parental permission obtained for DNA harvesting?	O Yes O No



### FORM 2: **DEMOGRAPHICS DATA**



2.1.	MOTHER'S AGE:	AF	D	MA	GE
------	---------------	----	---	----	----

- ETHNIC ORIGIN OF MOTHER: (self identified select one) APDETH 2.2.
  - 1 O Hispanic or Latino O NOT Hispanic or Latino O Unavailable/Unknown
- RACIAL ORIGIN OF MOTHER: (self identified select all that apply)

10 White APDRACWH

10 American Indian/Alaska Native APDRACAI

**APDRACBL** OBlack or African American

10 Native Hawaiian or other Pacific Islander

APDGRAV

10 Asian APDRACAS

1 O Unavailable/Unknown APDRACNA

- 2.4. MATERNAL EDUCATION: (select one) APDEDU
  - O Some education, high school not complete 1.50 Some college
  - 1 O High school graduate 3 O Graduate study
  - 80 Unknown/Unavailable 20 College graduate
- 2.5. MATERNAL MEDICAL HISTORY: (current)

2.5.a.	Diabetes (Any)	O Yes O No O Unknown	<b>APDDIA</b>
2.5.b.	Hypertension (Any)	10 Yes 00 No 80 Unknown	<b>APDHYP</b>
2.5.c.	Asthma	1 O Yes 0 O No 8 O Unknown	APDAST
2.5.d.	PPROM	10 Yes 00 No 80 Unknown	<b>APDPPR</b>

#### 2.6. PREGNANCY HISTORY:

- 2.6.a. Gravida (Total number of pregnancies, including current):
- APDPARA 2.6.b. Para (Total number of live births - number should include this birth):
- 2.6.c. Multiple gestation this birth: 20 Twin 30 Triplet 40 Quad 00 No 80 Unknown

**APDIUD** 

**APDMTW** 2.6.c.i. Is this infant a member of a monozygous twin? O YesOO No O Unknown 1 O Yes O No 80 Unknown 2.6.c.ii. Was there an intrauterine demise?

2.6.d. Pre-Natal Care: O Yes O No O Unknown

- MATERNAL CORTICOSTEROID ADMINISTRATION: APDCORT 2.7.
  - 2.7.a. Did mother receive antenatal corticosteroids? 10 Yes 00 No 80 Unknown

APDCORTFU 2.7.a.i. Was this a full course of corticosteroids? 10 Yes 00 No 80 Unknown (see MOP for definition)

Draft



### **FORM 3: INFANT DELIVERY DATA**

Screening ID#	Secondary ID	Staff Initials	Randomization #
. AIDID	AIDACRO	AIDST OS	FID AIDRANDN

3.1.	GENDER: <sup>1</sup> O Female <sup>0</sup> O Male AIDGEND
3.2.	BIRTH WEIGHT: gms AIDWTG
3.3.	PHYSICAL MEASUREMENTS AT BIRTH: Head Circumference (to the nearest 0.5cm):  AIDHEADC to Unknown AIDHCU
3.4.	DELIVERY ROUTE: O Vaginal O Caesarean O Unknown AIDDERT
3.5.	APGAR SCORES: 3.5.a. One Minute Not recorded AIDAP1N
	3.5.b. Five Minute Not recorded AIDAP5N
	ADAP10 3.5.c. Ten Minute Not recorded AIDAP10N
3.6.	DELIVERY RESUSCITATION REQUIRED: 10 Yes 00 No 80 Unknown
	3.6.a. Type of resuscitation (select all that apply)
	10 Oxygen AIDOXY 10 Intubation/Ventilation 10 NCPAP AIDNCPAP
	10 Bag and Mask Ventilation 10 Chest Compressions 10 Epinephrine
	ADDITION ADDITION


3.7. SURFACTANT THERAPY PRIOR TO ENROLLMENT: AIDSURF 10 Yes 00 No 80 Unknown

3.7.a. List all surfactant the	FOR ALL BELOW					
Date of Dose (mm/dd/yy)	Time (24 hour clock)	1 Survanta	2 Infasurf	<b>3</b> Curosurf	4 Other	
1. AIDSTDT1 /	AIDSTTH1 AIDSTTI	ALDS1	Г <b>В1</b> <sub>О</sub>	0	0	
2. AIDSTDT2 /	AIDSTTH2 AIDSTT	AIDS1 M2	<b>B2</b>	0	0	
3. AIDSTDT3 /	AIDSTTH3 AIDSTT	AIDS <sup>*</sup>	<b>TB3</b> <sub>O</sub>	0	0	
4. AID6TDT4 /	AIDSTTH4 AIDSTT	AIDS M4	<b>ΓΒ4</b> <sub>Ο</sub>	0	0	



### FORM 4: PRE-ENROLLMENT CO-MORBIDITIES OF PREMATURITY





4.1. NEUROLOGIC: Pre-Enrollment CMRIVH

10 Yes 00 No 80 Unknown 4.1.a. IVH:

> O Unilateral Grade 3 - 4 CMRIVHGRD OGrade 1 or 2 4.1.a.i. IVH Grade: <sup>1</sup>o MRI<sup>1</sup>o HUS<sup>1</sup>o C 4.1.a.ii. How was IVH determined? (select all that a MRIVHMRI CMRIVHHUS (Nb MRI/HUS/CT scan done)


4.1.b. Cystic PVL: CMRPVL 10 Yes no No **8**O Unknown

CMRPVLCTS CMF O MRI O HUS O CT Scan O Unknown 4.1.b.i. How was PVL determined? (select all that approximately controlled that approximately contr


#### 4.2. GASTROINTESTINAL: Pre-Enrollment

4.2.a. NEC:

NEC is defined as: pneumotosis, hepato-biliary gas, or pneumoperitoneum AND with one or more of the following: bilious gastric aspirate or emesis, abdominal distension, or occult or gross blood in stool not from fissure.




#### 4.2.b. Isolated GI Perforation without NEC:



#### 4.3. PULMONARY: Pre-Enrollment

4.3.a. Severe Pulmonary Interstitial Emphysema (PIE): (see MOP for definition)




Draft




## **TOLSURF**

### FORM 4: PRE-ENROLLMENT CO-MORBIDITIES OF PREMATURITY



**4.3.b. Severe Pulmonary Hemorrhage:** (see MOP for definition)

**CMSPUL** 



4.3.c. Pneumothorax (requiring a chest tube): **CMSPNE** 



#### 4.4. CARDIOVASCULAR: Pre-Enrollment


4.4.a. Was infant treated with prophylactic Indomethacin/Ibuprofen?

**CMSINDIBU** 10 Yes 00 No 80 Unknown


**4.4.b. PDA requiring treatment:** (see MOP)

1 O Yes OO No 80 Unknown

**CMSPDAT** 



4.4.c. Hypotension:



4.4.c.i. Treated w Dopamine > 20 mcg/kg/min > 24 hours CMSDOP 10 Yes 0 No 80 Unknown


4.4.c.ii. Treated w 2 or more pressor agents > 24 hours (includes hydrocortisone) 1<sub>O Yes</sub> 0<sub>O No</sub> 8<sub>O</sub> Unknown **CMSPRESS** 

TOLSURF Randomized&FollowUp Packet\_v2.5 (04/23/2013)




### **TOLSURF**

### FORM 4: PRE-ENROLLMENT CO-MORBIDITIES OF PREMATURITY



#### 4.4. CARDIOVASCULAR: Pre-Enrollment (cont.) **CMTPHY**


**4.4.d. Pulmonary Hypertension:** (see MOP) 1 Q Yes 0 Q No 8 Q Unknown



### 4.5. CULTURE PROVEN SEPSIS: Pre-Enrollment

Record for blood, CSF, urine, or TA culture samples. Record the dates of each positive sample drawn for each episode of sepsis/infection that resulted in treatment with antibiotics, antifungals or antivirals for > 7 days.

4.5.a. Did infant have culture proven sepsis?



4.5.b. Did infant have RSV pneumonia? 10 Yes 0 0 No 80 Nuknown **CMTRSV** 

4.5.b.i. Date first positive TA culture or DFA collected:

O No O Unknown

### FORM 5: PRE-ENROLLMENT RESPIRATORY PARAMETERS

. ( )	1 <b>\</b> 1	JKŀ
	LJU	JINI

Screening ID#	Secondary ID	Staff Initials	Page #	Randomization #
	AACRO 1ACRO	(Dra	PR1PAGEN Page of 5	PRARANDN PR1RANDN

	Draf	Ŗ	
iratory atus de) *			

Date of Birth (mm/dd/yy): (fake field)									
Hour	DOL	ges from birth up to da Date (mm/dd/yy)	Time (24 hr)	PEEP/ CPAP	MAP	Fi O <sub>2</sub>	NC Flow LPM	iNO ppm	Respiratory Status (code) *
PRADO	D.HR								
hr	D:								
hr	D:	PRARDATE							
hr	D:	/ / / PRA	TIMEH						
hr	<b>D</b> :		PRATIMEN						
hr	<b>D</b> :		: PR	APEEP		•			
hr	D:			PF	RAMAP				
hr	<b>D</b> :		•			PRAFIO2			RARCOD
hr	<b>D</b> :						PRANCE	PRAI	NO



EACH LINE REPRESENTS ONE RECORD WHICH WILL INCLUDE BANNER INFO. (DATE AND TIME OF BIRTH ARE FAKE FIELDS)

PRADOLHR is a combo of the first 2 columns, and the data will look like 4=CPAP this: 0801. The master table has added fields that are a subset of this field and they are PRAHR and PRADOL.

Respiratory Support Status:

1=CMV

2=HFV

3=NIMV (Nasal IMV, SiPAP, BiPAP)

5= HFNC or NC > 2 lpm

6=O2:NC (< 2 lpm or Oxyhood) 7=Ext in RA, off all support

	FORM 6:
Draft	•
TOI	SURF

INHALED NITRIC OXIDE DELIVERY


Screening ID#	Secondary ID	Staff Initials	Randomization #
INOID	INOACR	NOST OS	INORANDN

#### Box 1: Inhaled Nitric Oxide start and dosing schedule per NO CLD Protocol. (see MOP)


- 1 Initiate iNO at 20 PPM
- 2 Wean to 10 PPM at 4 days ± 24 hours after iNO started
- 3 Wean to 5 PPM at 11 days ± 24 hours after iNO started
- 4 Wean to 2 PPM at 18 days ± 24 hours after iNO started
- 5 Discontinue at 25 days ± 24 hours after iNO started

#### NOTE: USE OF INO PRIOR TO DOL 7 IS NOT PART OF THE TOLSURF STUDY

6.1. Report date/time iNO treatment began and concentration at iNO start.



6.2. Received additional iNO after completing iNO course per NO CLD Protocol? INOADDINO Yes Q 1 No On Unknown O 8




6.3. Date iNO discontinued:



### FORM 7A: INITIAL STUDY DRUG DELIVERY TOI SURF





Infant required reintubation - If Yes, enter on Form 13A: AE, Q13A.19. DRAINT

7A.2.b. Study drug dose/sham #1 tolerance, WITHIN <=24 HOURS AFTER DOSING PROCEDURE:

7A.2.b.i. 10 Yes 0 No Severe PIE - If yes, enter on Form 13A: AE, Q13A.5. and complete Form 21: SAE, Q21.4. DRAPIE

Severe Pulmonary Hemorrhage - If Yes, enter on Form 13A: AE, Q13A.6. & complete Form 21: SAE, Q.21. DRAPULM 7A.2.b.ii. 10 Yes **\text{\$\text{\$0}}** No

7A.2.b.iii. **1**O Yes **0**O No Pneumothorax requiring chest tube - If Yes, enter on Form 13A: AE, Q13A.7. & complete Form 21: SAE, Q21.6.

TOLSURF [DRA] v2.0, 08/06/10

FORM 7B: SUBSEQUENT STUDY   Screening ID#   Secondary   Staff Initials   Randomization #	
TOLSURF DRUG DELIVERY DRBLD DRBACROS DRBRANDN	
	₩Γ
	Draft ■
7B.1.a. Was this study drug dose/sham administered within <u>1 - 2 days after previous dose?</u> No O Yes O Go to Q7B.1.b.	
7B.1.a.i. Primary reason this study drug dose/sham was not given within 1- 2 days after previous dose:  10 Discontinued study drug/sham  This form is complete.  Complete Form 20: Study Drug Discontinuation Form  This form is complete. Complete Form 17: Death Report and Form 21: SAE, Q21.1.	
Delayed - Infant extubated 7B.1.a.ii. Was this study drug/sham dose subsequently administered? (Follow to DOL	$\Box$
75. Takin. Was this state the state that	
60 Delayed - weekend/holiday ————————————————————————————————————	
7O Study drug dosing error (see MOP) ——— Complete Form 19: Protocol Violations, Q19.2.e.	
7B.1.b. Tracheal Aspirate obtained prior to this study drug dose/sham? Yes ODRBTAO No OO N	<b>M</b> C
7B.1.c. Was there a problem with Tracheal Aspirate sampling? 1 Yes O Enter on Form 13A: Adverse Events, Q13A.20.  DRBTAPROB (see MOP) No O	
7B.1.d. Is infant currently receiving Inhaled Nitric Oxide? Yes ONO ON TRANSPORT TO THE PROPERTY OF THE PROPER	
7B.2 STUDY DRUG/SHAM - DATE & TIME DOSE GIVEN:  Vent Mode    DRB/SURD   DRB/SURD   If possible, please avoid suctioning DRB/Surp   DRB/Surp   DRB/Surp   If possible, please avoid suctioning DRB/Surp   DR	for
Time CMV or HEV PIP/\(\triangle\)PEP MAP Fi O2 O2 Sat	
O (pre) PRB THO O DRBPIPO DRBPEEPO DRBMAPO DRBFIO DRBQ2SO	
I ALIIII URDVIVIV	
2hr post DRBTH2 DRBVM2 DRBPIP2 DRBPEEP2 DRBMAP2 DRBFI2 DRBO2S2	
7B.2.a. Study drug dose/sham tolerance, WITHIN <=4 HOURS AFTER DOSING PROCEDURE:	
Severe respiratory decompensation (defined as increased RSS > 5 above baseline sustained > 24hr) - If Yes, enter on Form 13A: AE, Q13A.3. and complete Form 21: SAE, Q21.2.	
Sustained > 24hr) - If Yes, enter on Form 13A: AE, Q13A.3. and complete Form 21: SAE, Q21.2.  Severe cardiopulmonary decompensation requiring CPR with chest compressions and	
DRBINT cardiac meds - If Yes, enter on Form 13A: AE, Q13A.4. and complete Form 21: SAE, Q21.3.	
7B.2.a.iii.1○ Yes 00 No Reintubation required during or ≤ 4 hrs of dosing - If Yes, enter on Form 13A: AE, Q13A.19.	
<b>TB.2.b. Study drug dose/sham tolerance, WITHIN &lt;=24 HOURS AFTER DOSING PROCEDURE:</b> □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □	
7B.2.b. Study drug dose/snam tolerance, <u>WITHIN &lt;=24 HOURS AFTER DOSING PROCEDURE:</u> 7B.2.b.i. 10 Yes 00 No Severe PIE - <i>If Yes, enter on Form 13A: AE, Q13A.5. and complete Form 21: SAE, Q21.4.</i> DRBPUL	_M
7B.2.b.ii. 10 Yes 00 No Severe Pulmonary Hemorrhage - If Yes, enter on Form 13A: AE, Q13A.6. and complete Form 21: SAE, Q21.	
7B.2.b.iii. 10 Yes 00 No Pneumothorax with chest tube - If Yes, enter on Form 13A: AE, Q13A.7. and complete Form 21: SAE, Q21.6.  TOLSURE (DRB) v3.0.02/08/11	_ [
101NDRF1DRR1V3.0-07/0X/11	

### FORM 8: STUDY DAY 0 - 31 RESPIRATORY PARAMETERS

_			
	11		JRF
	\ <i>J</i>	1 . 71	$\mathbf{J}\mathbf{\Gamma}$
	` '		, , , ,

Screening ID#	Secondary ID	Staff Initials	Randomization #	Page #
PRBID PRI	ACROS	S	PRBRANDN	PRBPAGEN
	R2ACR	S	PR2RANDN	Pager2PACEN



Date of Stu	udy entry (mi	m/dd/yy): (fake field		y Day (SD) 00 Dat d on Form 7A, Q7		nitial Study	drug do	se/sham
Complete	these page	s from Study Day 00 (		Study Day 31 (SI				
Hour	Study day	Date (mm/dd/yy)	Time (24 hr)	PEEP/ CPAP MAP	Fi O2	NC Flow LPM	iNO ppm	Respiratory Status (code)*
PRB hr	SDHR SD		: p	RBPEEP			PRBIN	ю 🗌
hr	SD	PRBRDATE		PRBMAF	<u>.</u>	PRENCE		PRBRCODE
hr	SD	/ / / / / / / / / / / / / / / / / / /	MEH . PRBTIMEM		PRBFIO2			
hr	SD							
hr	SD							
hr	SD							
hr	SD							
hr	SD							
hr	SD							
	ACH I INE	REPRESENTS ON	DECORD W		CLUDE * F	espiratory Sur	port Stat	us:

■■ Draft **EACH LINE REPRESENTS ONE RECORD WHICH WILL INCLUDE**\* Respiratory Support Status
1=CMV
2=HFV


PRBSDHR is a combo of the first 2 columns, and the data will look line NIMV (Nasal IMV, SiPAP, BiPAP) this: 0801. The master table has added fields that are a subset of this HFNC or NC > 2 lpm field and they are PRBHR and PRBSD.


6=02:NC (≤ 2 lpm or Oxyhood) 7=Ext in RA, off all support

TOLSURF [PRB] v1.0, 01/08/10

FORM 9A: STUDY DAY 32 - 120 RESPIRATORY PARAMETERS

Т	$\cap$	ı				Г
ı		Н			R	⊢
- 1	U	'L	ال	U	' I \	ı





7=Ext in RA, off all support

### FORM 9B: STUDY DAY 121 - DISCHARGE RESPIRATORY PARAMETERS



Secondary Staff Screening ID# Additional Form 9B#s Randomization # **Initials** ARPADDN
Enter a sequential # here for each ARPACROS A 52779By sed for this infant, (e.g. RZACROS



•	Entry (mm/dd/yy): <b>(fake</b> orm until infant is discharge		found on I	/ (SD) 00 I Form 7A,		of Initial Stud	dy drug d	lose/sham
Study day	Date (mm/dd/yy)	Time (24 hr)	PEEP/ CPAP	MAP	Fi O2	NC Flow LPM	iNO ppm	Respiratory Status (code)*
SD ARPSD						•	A	RPRCODE
SD	ARPRDATÉ				•			
SD	/ / AR	PTIMEH						
SD		ARP:TIMEN			•	•		
SD		: .	ARPPE	P	•	•		
SD		:		ARPMAI		•		
SD					AR-PFIO2	•		
SD					•	ARPNCF		
SD							ARPIN	0
						**Respirator	y Support S	Status:

Will another Form 9B: Study Day 121 - Discharge Respiratory Parameters be used for this infant?

**FAKE FIELD** 

O Yes O No

EACH LINE REPRESENTS ONE RECORD WHICH WILL INCLUDE **BANNER INFO** 

1=CMV

2=HFV

3=NIMV (Nasal IMV, SiPAP, BiPAP)

4=CPAP

5= HFNC or NC >2 lpm

6=O2:NC (< 2 lpm or Oxyhood)

7=Ext in RA, off all support

TOLSURF [ARP] v1.0, 01/08/10



### FORM 10A: EXTUBATION DATA Secondary Staff

Screening ID#	Secondary ID	Staff Initials	Randomization #
EXTID	EXTS EXTACR	TFID OS	EXTRANDN

10.1 <u>EXTUBATION</u> (see MOP for instructions ) 10.1.a. Was infant extubated? Yes No <b>EXTEXTUB</b>
10.1.a.i. Date initially extubated: EXTEXP1 / EXTEXH1 Time: 24 hour clock
10.2 WAS INFANT REINTUBATED? 10 Yes 0 O No EXTRINTUB
10.3 RECORD OF REINTUBATION(S) (Do not include elective reintubations after self-extubation or ET tube changes)
10.3.a. Date reintubated: / EXTRED1 Time: 24 hour clock
10.3.a.i. Reason reintubated: <b>EXTREREA1</b>
O Failed nasal CPAP (see MOP for definition)
<sup>1</sup> O Recurrent apnea and bradycardia <sup>3</sup> O Other
10.3.a.ii. 2nd extubation date: EXTEXD2 / EXTEXM2 Time: EXTEXM2
10.3.b. Date reintubated:
10.3.b.i. Reason reintubated: <b>EXTREREA2</b>
O Failed nasal CPAP (see MOP for definition) Surgery
<sup>1</sup> O Recurrent apnea and bradycardia <sup>3</sup> Other
10.3.b.ii. 3rd extubation date: EXTEXN3  Month Day  Month Time: EXTEXN3  Year  Time: 24 hour clock
10.3.c. Date reintubated: Month / Day Year EXTREM3  Year EXTREM3  24 hour clock
10.3.c.i. Reason reintubated: <b>EXTREREA3</b>
Failed nasal CPAP (see MOP for definition) 20 Surgery
10 Recurrent apnea and bradycardia 30 Other
10.3.c.ii. 4th extubation date: EXTEXH4 Fine: EXTEXH4 Fine: 24 hour clock

Use Form 10B: Additional Extubation Data to document additional extubations.

10A.4 Will additional extubations be documented on Form 10B: Additional Extubation Data?

10 Yes 0 O No EXTADEXTFM





### FORM 10B: ADDITIONAL EXTUBATION DATA



No O-10B.1 Will additional extubations be reported below? Yes O Form complete **EX2ADDEX** (Do not include elective reintubations after self-extubation 10B.2 RECORD OF REINTUBATION(S) or ET tube changes) EX2REH4 2RED4 10B.2.a. Date reintubated: Time: 10B.2.a.i. Reason reintubated: **EX2REREA4** O Failed nasal CPAP (see MOP for definition) 2 O Surgery 1 O Recurrent apnea and bradycardia 3 O Other EX2EXH5 EX2EXM5 10B.2.a.ii. 5th extubation date: Time: 2REM5 10B.2.b. Date reintubated: 10B.2.b.i. Reason reintubated: **EX2REREA5** O Failed nasal CPAP (see MOP for definition) 2 O Surgery 3 O Other 1 O Recurrent apnea and bradycardia 10B.2.b.ii. 6th extubation date: Year EX2RE Time: 10B.2.c.Date reintubated: 24 hour clock 10B.2.c.i. Reason reintubated: **EX2REREA6** 20 Surgery O Failed nasal CPAP (see MOP for definition) 30 Other 10 Recurrent apnea and bradycardia EX2EXM7 10B.2.c.ii. 7th extubation date: 24 hour clock 10B.2.d. Date reintubated: Time: 24 hour clock 10B.2.d.i. Reason reintubated: **EX2REREA7** 20 Surgery O Failed nasal CPAP (see MOP for definition) 30 Other 1 O Recurrent apnea and bradycardia EX2EX Time: 10B.2.d.ii. 8th extubation date: Month 24 hour clock






### **TOLSURF**

Screening ID#	Secondary ID	Staff Initials	Randomization #
CMMID		ROS MMST	CMMRANDN FID

### 11A.1. NEUROLOGIC: Dosing Period (Enrollment to 7 days after final dose)

#### 11A.1.a. IVH:



### 11A.1.b. Cystic PVL:


<b>_</b>	Yes 00 No 80 Unknown
11A.1.b.ii. How was Cystic (select al.	PVL determined? 10 MRI O HUS10 CT Scan10 Unknown    that apply)
11A.1.b.iii. Cystic PVL is nev	w or worsened since Enrollment?
10 Yes	Enter on Form 13A: Adverse Events, Q13A.9.
00 No 80 Unknown	CMMPVLNW

11A.1.c. Hydrocephalus requiring shunt: 1 O Yes O No 8 O Unknown **CMMHYD** Enter on Form 13A: Adverse Events, Q13A.10.

### 11A.2. GASTROINTESTINAL: Dosing Period (Enrollment to 7 days after final dose)

NEC is defined as: pneumotosis, hepato-biliary gas, or pneumoperitoneum AND with one or more of the following: bilious gastric aspirate or emesis, abdominal distension, or occult or gross blood in stool not from fissure

### 11A.2.a. NEC (see MOP):







od (Enrollment to 7 days after final dose)


Secondary Staff Secondary Secondar


### TOLSURF






### 11A.3. PULMONARY: Dosing Period (Enrollment to 7 days after final dose)







### 11A.3.c. Pneumothorax requiring chest tube:




#### 11A.3.d. Tracheomalacia:



#### 11A.3.e. Tracheal stenosis:



#### 11A.3.f. Vocal chord paralysis:






Screening ID#	Secondary ID	Staff Initials	Randomization #
CMOID	MOACE	NO O O	TFID CMORANDN

### **TOLSURF**

### 11A.4. CARDIOVASCULAR: Dosing Period (Enrollment to 7 days after final dose)



Draft

Ш

Dav

Year

Month



Dosing Period (Enrollment to 7 days after final dose)

_	$\frown$			
11		LSI		
		71	R	
		_ 、 / \	 	

Screening ID#	Secondary ID	Initials	Randomization #
CMPID	CMPAC	CMPS ROS	TFID

### 11A.5. CULTURE PROVEN SEPSIS: Dosing Period (Enrollment to 7 days after final dose)

Record for blood, CSF, urine, or TA culture samples. Record the dates of each positive sample drawn for each episode of sepsis/infection that resulted in treatment with antibiotics, antifungals, or antivirals for  $\geq$  7 days CMPSEP

11A.5.a. Did infant have culture proven sepsis?

Note: If infant was on abx and death due to sepsis occurred without a positive culture or abx given for < 7 days, please mark "Yes" (see MOP).


Enter on Form 13A: Adverse Events, Q13A.23.

10 Yes 00 No 80 Unknown

	<b>▼</b>
Date specimen drawn:  CMPSD1/  Day  Year	Specimen type: (select one) 10 blood 20 CSF 30 Urine 40 TA CMPSPE1 Organism: (select all that apply) 10 Bacterial 10 Fungal 0 Viral CMPBAC1 CMPFUN1 1
Date specimen drawn:  CMPSD2/  Month  Day  Year	Specimen type: (select one) 10 blood 20 CSF 30 Urine 40 TA CMPSPE2 Organism: (select all that apply) 10 Bacterial 10 Fungal 0 Viral CMPBAC2 CMPFUN2 1
Date specimen drawn:  OMP\$D3/  Day  Year	Specimen type: (select one) 10 blood 20 CSF 30 Urine 40 TA CMPSPE3 Organism: (select all that apply) 10 Bacterial 10 Fungal 0 Viral CMPBAC3 CMPFUN3 1
Date specimen drawn:  Month  Day  Year	Specimen type: (select one) 10 blood 20 CSF 30 Urine 40 TA CMPSPE4 Organism: (select all that apply) 10 Bacterial 10 Fungal 0 Viral CMPBAC4 CMPFUN4 1
Date specimen drawn:  Month  Day  Year	Specimen type: (select one) 10 blood 20 CSF 30 Urine 40 TA CMPSPE5 Organism: (select all that apply) 10 Bacterial 10 Fungal 00 Viral CMPBAC5 CMPFUN5 1
Date specimen drawn:  CMP\$D6/  Month  Day  Year	Specimen type: (select one) 10 blood 20 CSF 30 Urine 40 TA CMPSPE6 Organism: (select all that apply) 10 Bacterial 10 Fungal O Viral CMPBAC6 CMPFUN6 1
Date specimen drawn:  ONIT Day  Page 1 Year	Specimen type: (select one) 10 blood 20 CSF 30 Urine 40 TA CMPSPE7 CMPVIR7 Organism: (select all that apply) 10 Bacterial 10 Fungal O Viral CMPBAC7 CMPFUN7 1
Date specimen drawn:    Day   PSDB   Year	Specimen type: (select one) 10 blood 20 CSF 30 Urine 40 TA CMPSPE8 Organism: (select all that apply) 10 Bacterial 10 Fungal 0 Viral CMPBAC8 CMPFUN8 1
Date specimen drawn:    Omega	Specimen type: (select one)10 blood 20 CSF 30 Urine 40 TA CMPSPE9 Organism: (select all that apply) 10 Bacterial 10 Fungal O Viral CMPBAC9 CMPFUN9 1




## TOLSURF



11A.5.b. Did infant have RSV pneumonia? **CMQRSV**  1 O Yes 0 O No 8 O Unknown

11A.5.b.i. Date first positive TA culture or DFA collected: CMQRSVD



Enter on Form 13A: Adverse Events, Q13A.28.

### 11A.6. OPHTHALMOLOGIC: Dosing Period (Enrollment to 7 days after final dose)

11A.6.a. Was ROP screening performed? **CMQROP** 

10 Yes 00 No 80 Unknown

11A.6.a.i. ROP Classification: (worst stage observed in either eye)

CMOROPCLAS ON NO ROP 1 O Stage 1

**2** O Stage 2

3 O Stage 3

40 Stage 4 5 O Stage 5 **8**0 Unknown O Not Applicable

If ROP Stage 1 - 5, enter Form 13A: Adverse event, Q11A.22.

10 Yes 00 No 80 Unknown CMQROPSUR 11A.6.a.ii. Was ROP surgery performed? (laser, cryo, etc.) CMQROPSURD 11A.6.a.iii. Date of surgery: Month Day Year



### FORM 11B: CO-MORBIDITIES OF PREMATURITY

Discharge Period (8 days after final dose to Discharge)

iait				
OL	Sl	R	F	

Secondary

Staff Randomization # **Initials** 

CMUID

CMUSTRID

### 11B.1. INFANT IN STUDY HOSPITAL AFTER DOSING PERIOD + 1 DAY?

CMUHOSR<sub>Yes O1</sub> No O

Form 11B is complete. Proceed to Form 12A

Unknown O 8

### 11B.2. NEUROLOGIC: Discharge Period (8 days after final dose to Discharge)

Screening ID#

11B.2.a. IVH: 10 Yes 00 No 80 Unknown CMUIVH

**CMUIVHUNK** 

CMUIVHCTS CMUIVH

11B.2.a.i. How was IVH determined? OMRI OCT Scan OHUS OUnknown (select all that apply) CMUIVHMRI CMUIVHH(USRI / CT Scan/HUS done)

11B.2.a.ii. IVH is new or worsened since Dosing Period?

CMUIVHNW<sup>0</sup>O No

**80** Unknown

2 O Unilateral Grade 3 - 4 3 O Bilateral Grade 3 - 4

Enter on Form 13B: CMUIMHGRD Adverse Events, Q13B.7.

11B.2.b. Cystic PVL: 1 O Yes O No 80 Unknown CMUPVL

1 CMUPVLCTS CMUPVLUNK

11B.2.b. i. How was Cystic PVL determined? O MRI10 CT Scan10 HUS10 Unknown
(select all that apply) CMUPVLMRI CMUPVLHUS No MRI / CT Scan/HUS done)

11B.2.b.ii. Cystic PVL is new or worsened since Dosing Period?

**CMUPVLNW** 

10 Yes — 

Enter on Form 13B: Adverse Events, Q13B.8.

**8**O Unknown

11B.2.c. Hydrocephalus requiring shunt: 10 Yes 00 No 80 Unknown

**CMUHYD** 

Enter on Form 13B: Adverse Events, Q13B.9.

#### 11B.3. GASTROINTESTINAL: Discharge Period (8 days after final dose to Discharge)

NEC is defined as: pneumotosis, hepato-biliary gas, or pneumoperitoneum AND with one or more of the following: bilious gastric aspirate or emesis, abdominal distension, or occult or gross blood in stool not from fissure.

**11B.3.a. NEC:** (see *MOP*)

CMUNEC

11B.3.a.i. NEC (newly diagnosed since Dosing Period): 1 Q Yes 0 O No 8 O Unknown

11B.3.a.ii. Date of diagnosis:

Enter on Form 13B: Adverse Events, Q13B.10.

**CMUNECTYPE** 

11B.3.a.iii. Outcome:

1 O NEC with surgery -(inc. peritoneal drain placement) 2 O NEC without surgery

**CMUNECSURD** 11B.3.a.iv. Date of surgery: Month Day


Enter on Form 14A, Hospital Course, Q14A.2.

Draft




### FORM 11B: CO-MORBIDITIES OF PREMATURITY

Discharge Period (8 days after final dose to Discharge)








0 No





### 11B.4. PULMONARY: Discharge Period (8 days after final dose to Discharge)
















11B.5.c.i. How was diagnosis determined: O Clinical O Echocardiogram O Unknown

11B.5.c.ii. How was diagnosis determined: O Clinical O Echocardiogram O Unknown

(select all that apply) CMWPHYCLI CMWPHYECH

11B.5.c.ii. Date of diagnosis: Month Day / Year Enter on Form 13B:

Adverse Events, Q13B.16.



### FORM 11B: CO-MORBIDITIES OF PREMATURITY Discharge Period (8 days after final dose to Discharge)

irge	e Period	(8 da <u>)</u>	ys after f	final do	ose to Discharge)
	Screen	ing ID#	Secondary ID	Staff Initials	Randomization #

$T \cap$		
111	I 🔪 I I	I₽⊦
$\mathbf{I} \mathbf{V}$	LJU	

Screening ID#	Secondary ID	Staff Initials	Randomization #
CMXID	MXAC	CMXS ROS	TFID CMXRANDN

### 11B.6. OPHTHALMOLOGIC: Discharge Period (8 days after final dose to Discharge)

11B.6.a. Was ROP screening performed? 10 Yes 00 No 80 Unknown

			<u> </u>	
11B.6.a.i.	ROP Classific	cation: (worst st	age observed in eit	ther eye) <b>CMXROPCLAS</b>
	O No ROP	10 Stage 1	2 O Stage 2	3O Stage 3
	40 Stage 4	<b>5</b> 0 Stage 5	80 Unknown	90 Not Applicable
	If ROP Sta	age 1 - 5, enter	on Form 13B: Adv	verse Events, Q13B.18.
11B.6.a.ii.	Was ROP sur	gery performed	? (laser, cryo, etc.)	10 Yes 00 No 80 Unknown
11B.6a. iii.	Date of surg	ery: Year / [	Day Year	CMXROPSURD

### 11B.7. CULTURE PROVEN SEPSIS: Discharge Period (8 days after final dose to Discharge)

Record for blood, CSF, urine, or TA culture samples. Record the dates of each positive sample drawn for each episode of sepsis/infection that resulted in treatment with antibiotics, antifungals, or antivirals for  $\geq 7$  days. CMXSEP

11B.7.a. Did infant have culture proven sepsis?

10 Yes 00 No 80 Unknown

Note: If infant was on abx and death due to sepsis occurred without a positive culture or abx given for Enter on Form 13B: Adverse Events, Q13B.19.

< 7 days, please mark "Yes" (see MOP).

CMXSPE1
Specimen type: (select one) 10 blood 20 CSF 30 Urine 40 Date specimen drawn: Organism: (select all that apply) CMXSPE2 Specimen type: (select one) 10 blood 20 CSF 30 Urine 40 TA Date specimen drawn: Organism: (select all that apply) O Bacterial 10 Fu CMXSPE3
Specimen type: (select one) 10 blood 20 CSF 30 Urine Date specimen drawn: Organism: (select all that apply) 10 Bacterial 10 Fungal Specimen type: (select one)10 blood 20 CSF 30 Urine 40 TA Date specimen drawn: CMXSD4 Organism: (select all that apply) O Bacterial 10 Fungal Month Day Year CMXSPE5 Date specimen drawn: Specimen type: (select one) 10 blood 20 CSF 30 Urine CMXSD5 Organism: (select all that apply) 10 Bacterial CMXSPE6 Specimen type: (select one) Oblood 20 CSF 30 Urine 40 TA Date specimen drawn: Organism: (select all that apply) Bacterial 10 Fungal





### FORM 11B: CO-MORBIDITIES OF PREMATURITY Discharge Period (8 days after final dose to Discharge)

### **TOLSURF**

Screening ID#	Secondary ID	Staff Initials	Randomization #
CMYID	CN YACRO	NYSTF \$	ID

(continued from previous page) Record additional episodes of sepsis below.






1 BP1PISD

**BP1PIS** 

TOLSURF [BP1] v3.0, 11/7/12



Page 1 of 1



12B.2.b.vi. Reason challenge test not done: (see MOP)

BP2OXCNR

O Not eligible for challenge test
1 O Infant at non-study facility
2 O Infant discharged home

3 O Eligible (in study hospital), but not done

Enter on Form 18: Protocol Deviation, Q18.2.g. and Go to Q12B.3.i.




12B.2.b.v. Challenge test results:

BP20XCHR ailed (Go to Q12B.3.i)

1 O Passed (Go to Q12B.3.ii)



### FORM 12B: BPD OUTCOMES - 40 WEEKS PMA





12B.3. <u>BPD STAT</u>	US WHEN 40 WEEKS PMA (± 1 week) FOR Survivors: (select one)
12B.3.i. Yes BPD O  BP3SURV	(Select one below) 10 Infant on nasal CPAP or ventilator or > 0.30 effective oxygen 20 Infant failed Oxygen reduction Challenge Test (or challenge not performed) 30 Infant now discharged or transfered ≤ 40 weeks and remains on continuous respiratory support (respiratory status codes 1 - 6)
12B.3.ii. <b>0</b> No BPD O	(Select one below) BP3NBPDR  4O Infant off continuous respiratory support  5O Infant passed Oxygen Reduction Challenge Test  6O Infant had no BPD at 36 weeks PMA
12B.3.iii. Unknown O	BP3
	D STATUS WHEN 40 WEEKS PMA, HAS BEEN REVIEWED BY INCIPAL INVESTIGATOR BP3PIS PI signed form? O Yes O No PI Initials:

1 BP3PISD



TOLS	SURF	FOR ADV	RM 13 ERS	3A: E E	VEI	VT:	S
		—		c	c		•

Screening ID # Secondary | Staff | Initials | Randomization # |

EZ1 ID | EZ1 ACROS | EZ1RANDN |

EZ1 ACROS | EZ1RANDN |

Dosing Period (Enrollment to 7 days	after final dose)	J <sup>-</sup>	<u> </u>	ROS		KANDNI			
13A.1. Did any co-morbidities reported on Form 11A or adverse events occur during the Dosing Period?  1 O Yes O No O Unknown  If "Yes", document below. PI must sign & date Form 13A, page 6. (See MOP)  EZ1 AES  TIME POINT:  Dosing Period  EZ1 VISIT									
13A.2. 10 Death 13A.2.a. Death occurred < 7 days after study drug dose/sham?									
EZ1DEA Yes10	Complete Form 17: Death Report AND Form 21: Serious Adverse Events, Q21.1.								
EZ1DEAOC NO	Complete Form 17: Death Repo	ort							
Adverse Events If occurance is "Yes" below, then report event on Form 21: SAE.	Date of Event (mm/dd/yy)	Severity	Relationship to Study Drug	Actions Taken	Outcome	Causality	Event Type		
13A.3. 10 Severe Respiratory Decompensation, EZ1RES	defined as RSS > 5 above b	aseline fo	or > 24 hrs.						
13A.3.a. Occured ≤ 4 hrs after dosing procedure?	_								
EZ1RESOC <sup>Yes</sup> No <sup>0</sup> O This is not a reportable Adverse Event									
13A.3.a.i. Enter on Form 21, SAE, Q21.2., and record SAE Form # here:	AEN								
13A.4. Severe Cardiopulmonary Decomper EZ1CPR	nsation, <u>requiring CPR with (</u>	thest con	pressions &	& cardiac					
13A.4.a. Occured ≤ 4 hrs after dosing procedure?	EZ1CPRD		EZ1CPR	2	EZ1CPF	RO	EZ1CPR		
EZ1CPROC Yes <sup>1</sup> O No <sup>0</sup> O									
13A.4.a.i. Enter on Form 21, SAE, Q21.3., and record SAE Form # here:	N	EZ1CP	RS	EZ1CPF	RA	EZ1CPF	RC		
All 6 pages of Form 13A must be fax Investigator must sign and date For	CODES FOR SEVERITY, RELATIONSHIP TO STUDY DRUG, ACTION TAKE, OUTCOME, CAUSALITY, AND EVENT TYPE ARE LOCATED AT THE BOTTOM OF PAGE 3.								

## TOLSURF FORM 13A: ADVERSE EVENTS

Dosing Period (Enrollment to 7 days after final dose)

Screening ID#	Secondary ID	Staff Initials	Randomization #
EZ2ID	EZ2ACR	Z2S 0 <b>S</b>	FID EZ2RANDN

Draft

TIME POINT: Dosing Period EZ2VISIT

Adverse Events  If occurance is "Yes" below, then report event on Form 21: SAE.	Date of Event (mm/dd/yy)	Severity	Relationship to Study Drug	Actions Taken	Outcome	Causality	Event Type
13A.5. O1 Severe PIE EZ2PIE	EZ2PIED		EZ2PIER		EZ2PIE		E-70 DIE
13A.5.a. Occured ≤ 24 hrs after dosing procedure?  EZ2PIEOC Yes 01 No0							EZ2PIE
13A.5.a.i. Enter on Form 21: SAE, Q21.4., and record SAE Form # here:		EZ2PII	ES .	EZ2PIE	A	EZ2PIE	
13A.6. O1 Severe Pulmonary Hemorrhage EZ2PUL	EZ2PULD		EZ2PULR		EZ2PUL	0	EZ2PUL
13A.6.a. Occured ≤ 24 hrs after dosing procedure?  EZ2PULOC Yes 01 No00							
13A.6.a.i. Enter on Form 21: SAE, Q21.5., and record SAE Form # here:		EZ2PU	LS	EZ2PUI	A	EZ2PUL	С
13A.7. Old Pneumothorax requiring chest tube EZ2PNE	EZ2PNED		EZ2PNER		EZ2PNE	0	EZ2PNE
13A.7.a. Occured ≤ 24 hrs after dosing procedure?  EZ2PNEOC Yes ○1 No0○→							
13A.7.a.i. Enter on Form 21: SAE, Q21.6., and record SAE Form # here:		EZ2PN	ES	EZ2PN	EA	EZ2PNE	C
All 6 pages of Form 13A must be faxed to DCC and Principal Investigator must sign and date Form 13A, page 6.			S FOR SEVE ON TAKE, OU' OCATED AT	TCOME, C	AUSALITY,	AND EVEN	, i

## ■ TOLSURF FORM 13A: ADVERSE EVENTS

Dosing Period (Enrollment to 7 days after final dose)

Screening ID#	Secondary ID	Staff Initials	Randomization #				
EZ3ID	Z3ACR	EZ3S	TFID EZ3RANDN				

				EZ3	BVISIT	<mark>39</mark> ● Dosing	Period
Adverse Events	Date of Event (mm/dd/yy)	Severity	Relationship to Study Drug	Actions Taken	Outcome	Causality	Event Type
13A.8. 10 IVH EZ3IVH	EZ3IYHD /	EZ3IVH		EZ3IVH <i>A</i>		EZ3IVHC	EZBIVHT
13A.9. <sup>1</sup> O Cystic PVL EZ3PVL	EZ3PYLD /	EZ <mark>3P</mark> VL		EZ3PVL	EZ <del>3P</del> VLC A	EZ3PVLC	EZ3₱VLT
13A.10. O Hydrocephalus EZ3HYD requiring shunt	EZ#HYDD /	EZ <mark>3H</mark> YI		<b>EZ3HYD</b>		EZ3HYDC	
13A.11. <sup>1</sup> O NEC EZ3NEC	EZ3NECD /	EZ3NEC	EZ3NECR S	EZ3NEC	EZBNECO A	EZ3NECC	EZ3NEC1
13A.12. O Isolated EZ3GIP GI Perforation	EZ3GIPD /	EZ3GIP	EZ3GIPR S	EZ3GIPA	EZ3GIPO	EZ3GIPC	EZ3GIPT
13A.13. O Tracheomalacia	EZ3MALD /	EZ3MA	EZ3MALR LS	EZ3MAL		EZ3MALC	EZ3MAL1
13A.14. <sup>1</sup> OTracheal EZ3STE Stenosis	EZ3STED /	EZ3STE	EZBSTER S	EZ3STE/	EZBSTEC	EZ3STEC	EZ3STET
13A.15. PDA requiring treatment	EZ3PPAD /	EZ3PD/	EZ3PDAR AS	EZ3PDA		EZ3PDAC	EZ3PDAT
13A.16. 1 Hypotension (when treated as reported on Q11A.4.b.)	EZ3HYPD /	EZ3HYF	EZ3HYPR	EZ3HYP	EZ3HYPC	EZ3HYPC	EZ3HYPT
13A.17. 10 Pulmonary EZ3PHY Hypertension	EZ3PHYD /	EZ3PH	EZ3PHYR YS	EZ3PHY	EZ3PHY	EZ3PHYC	EZ3PHYT
. —	3A must be faxed to DCC gator must sign and date	1=Mild 2=Moderate 3=Severe 4=Life-threat ening 8=Unavail able/unknowr (see MOP)	1=Not related 2=Unlikely 3=Possible 4=Probably 5=Definitely related 8=Unavailable/ Unknown	1=Not applicable 2=Study drug Discontinued 3=Standard care 8=Unavailable/ Unknown	Unknown	1=Not rel. to study drug 2=Concomitant med 3=Underlying condition 4=Study drug dosing 5=Unknown 6=Other	1=Expected 2=Unexpected v2.0, 06/28/10

### ■ TOLSURF FORM 13: ADVERSE EVENTS Dosing Period (Enrollment to 7 days after final dose)

**EZ4VISIT** Dosing Period39 Relationship **Actions** Type of to Study **Date of Event** Severity Causality Adverse Events Outcome Taken **Event** (mm/dd/yy) Drug EZ4PBD0 **EZ4PBDT** EZ4PBDR O 1 Prolonged 13A.18. **EZ4PBDD** EZ4PBD bradycardia/desaturation within 4 hours of dosing **EZ4PBDS EZ4PBDA** EZ4PBDC **EZ4ETPO O** 1 Endotracheal **EZ4ETPR EZ4ETPT** 13A.19. F74FTPtube problems requiring reintubation w/in 4hr of dosing EZ4ETPA EZ4ETPC **EZ4ETPS** O1 Problems **EZ4PTAT** EZ4PTAC **EZ4PTAR** 13A.20. obtaining Trachael Aspirate samples **EZ4PTAS** EZ4PTAA **EZ4PTAC EZ4UNXAET EZ4UNXAER** EZ4UNXAEO O<sup>1</sup> Unexpected **EZ4UNXAE** Adverse Event **EZ4UNXAES EZ4UNXAEC** 13A.21.a. This AE is related to **EZ4UNXAEA** Describe AE below: and occurred within, 7 days of study drug administration. **EZ4UNXAECM** 10 Yes 00 No \_\_\_\_ **EZ4UNXAENO** Complete SAE Form, Q21.7. and record SAE Form # here: EZ4ROPR **EZ4ROPO** EZ4R0PT 10 ROP 13A.22. **EZ4ROP** EZ4ROPC EZ4ROPS EZ4ROPA EZ4SP1R EZ4SP10 EZ4SP1T O Sepsis 13A.23. EZ4SP1S EZ4SP1A EZ4SP1C 1=Mild 1=Not related 1=Not 1=Not rel. to 1=Expected 1=Recovered/ 2=Unlikely 2=Moderate applicable Resolved study drug 2=Unexpected All 6 pages of Form 13A must be faxed to DCC 3=Severe 2=Study drug | 2=Improved 2=Concomitant 3=Possible and Principal Investigator must sign and date 4=Life-threat 4=Probably Discontinued 3=Unchanged med enina 5=Definitely 3=Standard 3=Underlying 4=Worsened Form 13A, page 6. 8=Unavailable related care condition 5=Death=SAE /Unknown 8=Unavailable/ 8=Unavailable/ 4=Study drug 8=Unavailable/ Unknown dosina (see MOP) Unknown Unknown 5=Unknown

TOLSURF [EZ4] v2.0, 06/28/10

6=Other

## TOLSURF FORM 13A: ADVERSE EVENTS EX51D

Screening ID # Secondary | Staff | Initials | Randomization # |

EZ5ID | EZ5RANDN | EZ5R

Dosing Period (Enrollment to 7 days after final dose)



				E	<b>Z5VISIT</b>	39● Dosing	g Period	
Adverse Events	Date of Event (mm/dd/yy)	Severity	Relationship to Study Drug	Actions Taken	Outcome	Causality	Event Type	
EZ5SP1 13A.24. 10 Sepsis	EZ5SP1D /	EZ5SP1	EZ5SP1R S	EZ5SP1/	EZ <del>5SP</del> 10	EZ5SP1C	EZ5SP1T	
13A.25. <b>EZ5SP2</b> O Sepsis	EZ5SF/2D /	EZ <del>5S</del> P2	EZ5SP2R	EZ5SP2	EZ <del>5S</del> P20	EZ <del>5S</del> P2C	EZ5SP2T	
13A.26. EZ5SP3 1 O Sepsis	EZ5S/P3D /	EZ5SP3		EZ5SP3/	EZ <del>5S</del> P30	EZ <del>SS</del> P3C	EZ5SP3T	
13A.27. <b>EZ5SP4</b> 10 Sepsis	EZ5SP4D /	EZ5SP4	S EZ <del>SS</del> P4R	EZ5SP4/	EZ5SP40	EZ5SP4C		
EZ5RSV 13A.28. 1 Pneumonia	EZ5R\$VD /	EZ5RS\	EZ <del>5R</del> SVR	EZ <del>5RS</del> V/	EZ5RSV	EZ5RSVC	EZ <del>5R</del> SVT	
EZ5VCP Vocal chord 10 paralysis	EZ5V¢PD /	EZ5VCF	EZ5VCPR	EZ <del>5V</del> CP/	EZ <del>5V</del> CPO	EZ <del>5V</del> CPC	EZ5VCPT	
Table 13A.30. O Other 1 Describe "Other" event below:	EZ50/TH1D /	EZ5OTH	EZ5OTH1F	EZ5OTH	EZ <del>5O</del> TH	10 EZ <del>50</del> TH1	EZ5OTH11	
EZ5OTH	1CM							
		A Mild	A Net related	4. Not	4 December 1	A Net rel te	4. Surported	
	13A must be faxed to DCC tigator must sign and date	1=Mild 2=Moderate 3=Severe 4=Life-threat ening 8=Unavailable Unknown (see MOP)	1=Not related 2=Unlikely 3=Possible 4=Probably 5=Definitely related 8=Unavailable/ Unknown	1=Not applicable 2=Study drug Discontinued 3=Standard care 8=Unavailable/ Unknown	1=Recovered/ Resolved 2=Improved 3=Unchanged 4=Worsened 5=Death=SAE 8=Unavailable/ Unknown	1=Not rel. to study drug 2=Concomitant med 3=Underlying condition 4=Study drug dosing 5=Unknown 6=Other	1=Expected 2=Unexpected	
Page 5 of 6  Page 5 of 6  TOLSURF [EZ5] v2.0, 06/28/10								

■ TOLSURF	FORM 13A: ADVERSE EVENTS
Dosing Period (Enrollme	nt to 7 days after final dose)

Screening ID# Secondary ID Randomization #

EZAACROS EZARANDN

EZASTIFID

Time Point: Dosing Period EZAVISIT

Adverse Events	Date of Event (mm/dd/yy)	Severity	Relationship to Study Drug	Actions Taken	Outcome	Causality	Event Type
13A.31. O Other EZAOTH2 Describe "Other" event below:	EZAOTH26	EZAOTH	EZAOTH2	R EZAOTH	EZAOTH 2A	20 EZAOTH20	EZAOTH2
EZAOTH2CM							
		1=Mild 2=Moderate 3=Severe 4=Life-threat ening 8=Unavailable Unknown	1=Not related 2=Unlikely 3=Possible 4=Probably 5=Definitely related 8=Unavailable/ Unknown	1=Not applicable 2=Study drug Discontinued 3=Standard care 8=Unavailable/ Unknown	1=Recovered/ Resolved 2=Improved 3=Unchanged 4=Worsened 5=Death=SAE 8=Unavailable/ Unknown	1=Not rel. to study drug 2=Concomitant med 3=Underlying condition 4=Study drug dosing 5=Unknown 6=Other	1=Expected 2=Unexpected
	I have reviewed all 6 pag		n 13A and it is	s accurate to		of my knowle  EZAPII  PI Initials:	edge.



1 EZAPISD Form signed? 1 O Yes 00 No

**EZAPIS** 

Date of signature:(mm/dd/yy)

# TOLSURF FORM 13B: ADVERSE EVENTS Discharge Period (8 days after final dose to Discharge)

Secondary ID Staff Initials Screening ID# Randomization # EZ6ACROS EZ6RANDN



	3B.1. Did any co-morbidities reported on Form 11B or adverse events occur during the Discharge Period?  Time Point:  1 O Yes 0 O No 8 O Unknown  EZ6AES  Discharge period  EZ6VISIT									
If	If "Yes", document below. Complete pages 1 - 4. PI must sign and date Form 13B, page 4. (See MOP)									
A	Adverse Events	Date of Event (mm/dd/yy)	Severity	Relationship to Study Drug	Actions Taken	Outcome	Causality	Event Type		
13B.2. <mark>1</mark> O	Death <b>EZ6DEA</b>	EZ6DEAD /	EZ6DE/	AS EZ <del>6D</del> EAR	EZ6DE/	AA EZ <del>6D</del> EAC	EZ6DEAC	EZ6DEAT		
13B.3. <b>1</b> O	Severe Cardiopulmo EZ6CPR	nary Decompensation, <u>requi</u>	ring CPR		EZ6CPF		EZ6CPRC	EZ6CPRI		
13B.4. <b>1</b> O	Severe PIE EZ6PIE	<b>EZ6PFD</b> /	EZ6PIE	S EZ6 <del>PI</del> ER	EZ6PIE	EZ6PJEO	EZ6PIEC	EZ <del>6P</del> IET		
13B.5. <b>1</b> O <b>EZ6PU</b>	Severe Pulmonary Hemorrhage	EZ6PULD /	EZ6PUL	S EZ6PULR	EZ6PUI	LA EZ <del>SP</del> ULC	EZ6PULC	EZ6PULT		
13B.6. <sup>1</sup> O EZ6PNE	Pneumothorax requiring chest tube	EZ6PNED /	EZ6PNE	S EZ6PNER	EZ6PNI	EZ6PNEC	EZ6PNEC	EZ6PNE		
Draft	. •	13B must be faxed to DCC gator must sign and date	1=Mild 2=Moderate 3=Severe 4=Life-threat ening 8=Unavailable /Unknown (see MOP)	4=Probably 5=Definitely	1=Not applicable 3=Standard Care 8=Unavailable Unknown	1=Recovered/ Resolved 2=Improved 3=Unchanged 4 4=Worsened 5=Death 8=Unavailable/ Unknown	1=Not rel. to study drug 2=Concomitant med 3=Underlying condition 4=Study drug dosing 5=Unknown 6=Other	1=Expected 2=Unexpected		

## TOLSURF FORM 13B: Scree ADVERSE EVENTS Discharge Period (8 days after final dose to Discharge)

Secondary ID Staff Screening ID# Randomization # Initials

EZ7VISIT Discharge period **Time Point:** 

						2 ● Discha	rge period
Adverse Events	Date of Event (mm/dd/yy)	Severity	Relationship to Study Drug	Actions Taken	Outcome	Causality	Event Type
<b>EZ7IVH</b> 13B.7. <b>1</b> O <b>IVH</b>	EZ7IVHD /	EZ7IVI	IS EZ7IVHR	EZ <del>7IV</del> H/	A EZ <mark>7IV</mark> HO	EZ7IVHC	EZ7IVHT
13B.8. 10 Cystic PVL EZ7PVL	EZ7PVLD /	EZ7PV	LS EZ <del>7P</del> VLR	EZ7PVL	A EZ7PVLO	EZ7PVLC	EZ7PVL1
13B.9. 10 Hydrocephalus EZ7HYD requiring shunt	EZ7HYDD /	EZ7HY	DS EZ7HYDR	EZ7HYC	A EZ7HYDO	EZ7HYDC	EZ7HYD'
13B.10. <b>1</b> O <b>NEC EZ7NEC</b>	EZ7NECD /	EZ7NE	CS ZNECR	EZ7NEC	A EZ7NECO	EZ7NECC	EZYNEC'
13B.11. 10 Isolated EZ7GIP GI Perforation	EZ7GIPD /	EZ7GIF	S EZ7GIPR	EZ <mark>7G</mark> IP	A EZ7GIPO	EZ7GIPC	EZ7GIP1
13B.12. <b>1</b> O <b>Tracheomalacia EZ7MAL</b>	EZ7MALD /	EZ7MA	LS EZ7 <u>M</u> ALR	EZ7MAL	.A EZ7MALO	EZ7MALC	EZ <del>7M</del> AL
13B.13. 10 Tracheal EZ7STEStenosis	EZ7STED /	EZ7\$T	ES EZ7STER	EZ <del>7S</del> TE	A EZ7STE	EZ7STEC	EZ7STE
13B.14. 10 PDA Requiring EZ7PDA Treatment	EZ7PD/AD /	EZ <del>7P</del> D	AS EZ7P <u>d</u> ar	EZ <del>7P</del> DA	A EZZPDA	EZ7PDAC	EZ7PDA'
13B.15. 10 Hypotension EZ7HYP (when treated as reported on Q11B.5.b.)	EZ7HYPD /	EZ7HYI	PS EZ7HYPR	EZ7HYP	A EZ7HYPO	EZ7HYPC	EZ <del>7H</del> YP
	13B must be faxed to DCC igator must sign and date	1=Mild 2=Moderate 3=Severe 4=Life-threat ening 8=Unavailabl /Unknown (see MOP	8=Unavailable/	1=Not applicable 3=Standard care 8=Unavailable /Unknown	1=Recovered/ Resolved 2=Improved 3=Unchanged 4=Worsened 5=Death 8=Unavailable/ Unknown	1=Not rel. to study drug 2=Concomitant med 3=Underlying condition 4=Study drug dosing 5=Unknown 6=Other	1=Expected 2=Unexpected

# TOLSURF FORM 13B: ADVERSE EVENTS

Secondary ID Staff Initials Screening ID# Randomization # EZ8ACROS **EZ8RANDN** 

EZ8ID Discharge Period (8 days after final dose to Discharge)

TIME POINT: **EZ8VISIT** 2 Discharge period

TOLSURF [EZ8] v2.0, 08/10/10

Adverse Events	Date of Event (mm/dd/yy)	Severity	Relationship to Study Drug	Actions Taken	Outcome	Causality	Event Type
13B.16. 10 Pulmonary Hypertension	EZ8P/HYD /	EZ8PHY	S EZ8PHYR	EZ <del>8P</del> HY	A EZ8PHYO	EZ8PHYC	EZ8PHYT
13B.17. 10 Unexpected Adverse Event	EZ8UNXAED /	EZBUNX		EZ8UNX	AEA EZ8UNX	EZ8UNXA	EZ8UNXAET
EZ8UNXAE	Describe AE:  EZ8UNXAECM		EZ8UNXA	EK	LLOON	nLO	LZOUIVALI
13B.18. 10 ROP EZ8ROP	EZ8RØPD /	EZ8ROF	S EZ <del>8R</del> OPR	EZ8ROP	A EZ <del>8R</del> OP(	EZ8ROPC	EZ8ROPT
13B.19. 10 Sepsis EZ8SP1	EZ8\$PID /	EZ8SP1	EZ8SP1R		EZ8SP10	EZ8SP1C	EZ8SP1T
13B.20. <sup>1</sup> O <b>Sepsis EZ8SP2</b>	EZ8\$P2D /	EZ8SP2	S EZ8SP2R	EZ8SP2	A EZ8SP20	EZ8SP2C	EZ8SP2T
13B.21. O Sepsis EZ8SP3	EZ8S/P3D /	EZ8SP3	S EZ8 <del>S</del> P3R	EZ8SP3	A EZ8 <del>S</del> P30	EZ8SP3C	EZ8SP3T
1 13B.22. O Sepsis EZ8SP4	EZ8SP4D /	EZ8SP4	S EZ8SP4R	EZ8SP4	A EZ8SP40	EZ8 <del>SP</del> 4C	EZ8SP4T
	n 13B must be faxed to DCC tigator must sign and date	1=Mild 2=Moderate 3=Severe 4=Life-threat ening 8=Unavailable /Unknown (see MOP)	1=Not related 2=Unlikely 3=Possible 4=Probably 5=Definitely related 8=Unavailable/ Unknown	1=Not applicable 3=Standard care 8=Unavailable/ Unknown	1=Recovered/ Resolved 2=Improved 3=Unchanged 4=Worsened 5=Death 8=Unavailable/ Unknown	1=Not rel. to study drug 2=Concomitant med 3=Underlying condition 4=Study drug dosing 5=Unknown 6=Other	1=Expected 2=Unexpected

# TOLSURF FORM 13B: ADVERSE EVENTS Discharge Period (8 days after final dose to Discharge)

Secondary ID Staff Screening ID# Randomization # Initials **EZ9RANDN** 

2 Discharge period

Adverse Events	Date of Event (mm/dd/yy)	Severity	Relationship to Study Drug	Actions Taken	Outcome	EZ9V Causality	Event Type
13B.23. 1 O Sepsis	EZ9SP1D /	EZ9SP	EZ9SP1R	EZ9SP1	A EZ9SP1C	EZ9SP1C	EZ9SP1T
EZ9RSV 13B.24. 1 Pneumonia	EZ9RŞVD /	EZ9RS	EZ9RSVR		EZ9RSVC		EZ9RSVI
EZ9VCP 13B.25. 10 Vocal chord paralysis	EZ9VCPD /	EZ9VC	EZ9VCPR	E <del>Z9V</del> CI	EZ9VCP	EZ9 <del>VC</del> PC	EZ9VCPT
13B.26. 10 Other Describe Other event below:	EZ9OTHID /	EZ90T	H1S EZ9 <del>OT</del> H1F	EZ9 <del>O</del> TH	1A EZ <del>90</del> TH1	EZ9 <del>OT</del> H10	EZ9OTH1
EZ9OTH1CM							
13B.27. 10 Other Describe Other event below:	EZ90TH2D /	EZ90T	H2S EZ9 <del>OT</del> H2R	EZ9 <del>O</del> TH	2A EZ <del>9O</del> TH2	EZ9 <del>OT</del> H2	C EZ <del>9</del> OTH2
EZ9OTH2CM							
I have reviewed all 4 accurate to the best  Principal Investigator Signed?  To Yes O No Page 10	PI Initials:	1=Mild 2=Moderate 3=Severe 4=Life-threat ening 8=Unavailab e/Unknown (see MOP)	5=Definitely	1=Not applicable 3=Standard care 8=Unavailable/ Unknown	1=Recovered/ Resolved 2=Improved 3=Unchanged 4=Worsened 5=Death 8=Unavailable/ Unknown	1=Not rel. to study drug 2=Concomitant med 3=Underlying condition 4=Study drug dosing 5=Unknown 6=Other	1=Expected 2=Unexpected

1 EZ9PISD



# FORM 14A: HOSPITAL COURSE WHILE AT STUDY HOSPITAL

Screening ID#	Secondary ID	Staff Initials	Randomization #
HC1ID	HC1AC	<del>  0</del> 18   08	TFID HC1RANDN

#### 14A.1. TPN (Total Parenteral Nutrition):

14A.1.a. Was infant given TPN solution?

#### **HC1TPNGVN**

Month Day Year	Month Day Year
14A.1.a.i. Start Date: HC1T/PNST1 /	End Date: HC1TPNEN1 /
14A.1.a.ii. Start Date: HC1T/NST2 /	End Date: HC1TPNEN2 /
14A.1.a.iii. Start Date: HC1TPNST3 /	End Date: HC1TPNEN3 /
14A.1.a.iv. Start Date: HC1TPNST4 /	End Date: HC1TPNEN4 /
14A.1.a.v. Start Date: HC1TPNST5 /	End Date: HC1TPNEN5 /
14A.1.a.vi. Start Date: HC1TPNST6 /	End Date: HC1TPNEN6 /
14A.1.a.vii. Start Date: HC1TPNST7 /	End Date: HC1TPNEN7 /
14A.1.a.viii Start Date: HC1TPNST8 /	End Date: HC1TPNEN8 /
14A.1.a.ix. Start Date: HC1T/NST9 /	End Date: HC1TPNEN9 /
14A.1.a.x. Start Date: HC1TPNST10/	End Date: HC1TFNEN10/
14A.1.a.xi. Start Date: HC1T/NST11/	End Date: HC1TPNEN11/
14A.1.a.xii. Start Date: HC1TPNST12/	End Date: HC1TFNEN12/
14A.1.a.xiii Start Date: HC1T/PNST13/	End Date: HC1TFNEN13/
14A.1.a.xiv. Start Date: HC1TFNST14/	End Date: HC1TFNEN14/



# FORM 14A: HOSPITAL COURSE WHILE AT STUDY HOSPITAL

Screening ID#	Secondary ID	Staff Initials	Randomization #
HC2ID	HC2AC	HC2\$	TFID HC2RANDN

14A.2. SURGERIES: (For Surgery Codes see MOP)
14A.2.a. Were any surgeries performed? 1 O Yes 0 No

·						
14A.2.a.i. Surgery Code: SHC2SCODE1 Date: HC2SDATE/						
14A.2.a.ii Surgery Code: SHC2SCODE2 Date: HC2SDATE2						
14A.2.a.iii. Surgery Code: SHC2SCODE3 Date: HC2SDATE3						
14A.2.a.iv. Surgery Code: SHC2SCODE4 Date: HC2SDATE4						
14A.2.a.v. Surgery Code: SHC2SCODE5 Date: HC2SDATE5						
14A.2.a.vi. Surgery Code: SHC2SCODE6 Date: HC2SDATE6						
14A.2.a.vii. Surgery Code: SHC2SCODE7 Date: HC2SDATE/						
14A.2.a.viii. Surgery Code: SHC2SCODE8 Date: HC2SDATE8						
14A.2.b. Have additional surgeries been performed? 10 Yes 00 No HC2ADDSUR						
If Yes, report these additional surgeries on FORM 14C: HOSPITAL COURSE - Additional Surgeries While at Study Hospital.						

14A.3. TRANSFUSIONS: (all blood products provided by Blood Bank)

14A.3.a. Was infant given any transfusions? 1 O Yes 00 No

14A.3.a.ii Date: HC27RAND2/ Number of transfusions: HC2TRANN1

14A.3.a.iii Date: HC27RAND3 Number of transfusions: HC2TRANN2

14A.3.a.iii. Date: HC27RAND3 Number of transfusions: HC2TRANN3

Report additional transfusions on Form 14B - Additional Transfusions

14A.3.b. Have addition transfusions been performed? 10 Yes 00 No HC2ADTRPER

Complete Form 14B: Additional Transfusions Form

Draft

14A.3.b.i. How many Form 14B: Additional Tranfusions forms were used?



#### FORM 14B: ADDITIONAL TRANSFUSIONS

Screening ID#	Secondary ID	Staff Initials	Randomization #	Add. Trans.#	
HCXID	CXACR	CXST	HCXRANDN HC	XADD	RAN

Each Form 14B faxed to the DCC, rerquires a unique number in the Add. Trans. # box above. For e.g. enter 01 on first form used, 02 on second form, 03 on third form, etc. An Add. Trans. # can only be used once. i.e. each form requires a unique #.

#### 14B.1. ADDITIONAL TRANSFUSIONS:

14B.1.a. Were additional transfusion/s performed? HCXTRANPER ONO

	HUXTRANI	- <u>LN</u> +
14B.1.a.i.	Date: HCXTRAND1/	Number of transfusions:
14B.1.a.ii.	Date: HCXTRAND2/	Number of transfusions: HCXTRANN2
14B.1.a.iii.	Date: HCX7RAND3/	Number of transfusions:
14B.1.a.iv.	Date: HCXT/RAND4/	Number of transfusions: HCXTRANN4
14B.1.a.v.	Date: HCXT/RAND5/	Number of transfusions: HCXTRANN5
14B.1.a.vi.	Date: HCXT/RAND6/	Number of transfusions:
14B.1.a.vii.	Date: HCXT/RAND7/	Number of transfusions: HCX TRANN7
14B.1.a.viii.	Date: HCXTRAND8/	Number of transfusions: HCX TRANN8
14B.1.a.ix.	Date: HCXTRAND9/	Number of transfusions:
14B.1.a.x.	Date: HCXTRAND16	Number of transfusions: HCXTRANN10
14B.1.a.xi.	Date: HCXTRAND11	Number of transfusions: TRANIN11
14B.1.a.xii.	Date: HCXT/RAND12	Number of transfusions:
14B.1.a.xiii.	Date: HCXTRAND15	Number of transfusions: HCXTRANN13
14B.1.a.xiv.	Date: HCXT/RAND14	Number of transfusions. HCXTRAINN14
14B.1.a.xv.	Date: HCXTRAND15 Month Day Year	Number of transfusions: HCXTRAINN15



# FORM 14C: ADDITIONAL SURGERIES WHILE AT STUDY HOSPITAL

Screening ID#	Secondary ID	Staff Initials	Randomization #
HCZID	HCZAC	HOZS OS	TFID . H¢zrandn

**14.C.1.** SURGERIES: (For Surgery Codes see MOP)

**HCZSURGPER** 

14C.1.a. Were any additional surgeries performed?

								Month	Day	Year	
14C.1.a.i.	Surgery	Code:	SH	CZSC	ODE	<b>1</b> D	ate:	HCZ	\$DAT	<b>E/I</b>	
14C.1.a.ii	Surgery	Code:	SH	CZSC	ODE	<b>2</b> D	ate:	HCZ:	DATE	<b>2</b>	
14C.1.a.iii.	Surgery	Code:	SH	CZSC	ODE	<b>3</b> D	ate:	HCZ:	DATE	<b>\$</b>	
14C.1.a.iv.	Surgery	Code:	SH	CZS	CODE	<b>4</b> D	ate:	HCZ:	DATE	<b>A</b>	
14C.1.a.v.	Surgery	Code:	SHO	CZSC	ODE	<b>5</b> D	ate:	HCZ:	DATE	<u></u>	
14C.1.a.vi.	Surgery	Code:	SHO	CZSC	ODE	<b>6</b> D	ate:	HCZ:	DATE	6	
14C.1.a.vii.	Surgery	Code:	SH	CZSC	ODE	<b>7</b> D	ate:	HCZ:	<b>SDATE</b>	<b>/</b>	
14C.1.a.viii	Surgery	Code:	SH	CZSC	ODE	<b>8</b> D	ate:	HCZ:	<b>SDATE</b>	8	
14C.1.a.ix.	Surgery	Code:	SH	CZSC	ODE	<b>9</b> D	ate:	HCZ:	<b>SDATE</b>	ø	
14C.1.a.x	Surgery	Code:	SH	CZSC	ODE	<b>10</b>	ate:	HCZ	\$DAT	<b>E/1</b> 0	
14C.1.a.xi.	Surgery	Code:	SH	CZSC	ODE	<b>11</b> D	ate:	HCZ:	<b>SDATE</b>	1 1	
14C.1.a.xii.	Surgery	Code:	SH	CZS	CODE	1 <b>2</b>	ate:	HCZ:	SDATE	<u>f</u> 12	
14C.1.a.xiii.	Surgery	Code:	SH	CZS	CODE	13	ate:	HCZ:	<b>SDATE</b>	<b>1</b> 3	
14C.1.a.xiv	Surgery	Code:	SHO	¢zsc	ODE	<b>14</b> D	ate:	H¢Z	<b>DATE</b>	14	
14C.1.a.xv.	Surgery	Code:	SH	CZSC	ODE	<b>15</b> D	ate:	HCZ:	<b>SDATE</b>	<b>f 5</b>	
14C.1.a.xvi	Surgery	Code:	SH	CZSC	ODE	<b>16</b>	ate:	HÇZ	DATE	16	



# FORM 15: MEDICATIONS WHILE AT STUDY HOSPITAL

# **TOLSURF**

Screening ID#	Secondary ID	Statt Initials	Randomization #
:MD1ID	MD1ACF N	OS ID1ST	FID MD1RANDN


15.1 SYSTEMIC CORTICOSTEROID ADMINISTERED?	♦ Yes ♦ No <sup>8</sup> O Unknown
(list all courses) MD1SYCOAD	<del>↓</del> MD1STDAOG1
MD1 CCTVDE1 Month Day Year N	AD1\$¢STOP1/ Tear Ongoing:
Type: (select one) O Dexamethason O Hydrocortiso	ne <sup>3</sup> 0 Other
Reason(s) given: 10 BPD 10 Adrenal insuff	iciency 10 Other
(select all that apply) 10 Hypotension 10 Extubation	MD1SCROT1
	<del>'``</del> <del>MD</del> 1SIDAOG2
15.1.b. Start Date: MD1 SCST AR2 Stop Date:	MD1\$CSTOP2 Ongoing:1
MD1SCTYPE2 Month 1 Day Year 2 Type: (select one) O Dexamethasone O Hydrocortisc	Month 3 Day Year One O Other
MD1SCRBPD2 MD1SCRA	12
Reason(s) given: 10 BPD 10 Adrenal insuff (select all that apply) 10 Hypotensian 10 Extubation M	iciency 10 Other MD1SCROT2
(select all that apply) 10 Hypotension 10 Extubation MD1SCRBP2	MD1STDAOGB
15.1.c. Start Date: MD/ISCSTA/R3 Stop Date:	MD1SCSTOP3 01
MD1SCTYPE3 Month 1 Day Year 2	Month Day / Lar Ongoing:
<b>Type:</b> (select one) O Dexamethasone O Hydrocortise	
MD1SCRBPD3 MD1SCRAI Reason(s) given: 10 BPD 10 Adrenal insuff	
(select all that apply)  10 Hypotension 10 Extubation M	D1SCREX3
15.1.d. Start Date: MD15CSTAR4 Stop Date:	
MD1SCTYPE4 1 Type: (select one) O Dexamethasone O Hydrocortise	Month 3 Pay Year
MD1SCRBPD4 MD1SCR Reason(s) given: 40 RPD Adrenal insuff	
Trouber (c) great 10 Bi B	iciency 10 Other MD1SCROT4
(select all that apply) O Hypotension O Extubation MD1SCRBP4	D1SCREX4
	MD/1SCSTØP5 STDAOG5
15.1.e. Start Date: MD/1SCSTAR5 Stop Date: Day Year	Month Day Year Ongoing:
Type: (select one) Of Devamethasone 20 Hydrocortis	one Othor
Reason(s) given: 10 BPD 10 Adrenal insuff	AI5 10 Other MD1SCROTE
(select all that apply)  10 Hypotension 10 Extubation	DASCREVE
MD1SCRBP5	MD1STDAOG6
15.1.f. Start Date: MD/1 SC ST A/R6 Stop Date:	
MD1SCTYPE6 Month Day Year	Month Day Year Ongoing:
Type: (select one) ODexamethasone CO Hydrocortisc	one 3 Other
Reason(s) given: 10 BPD 10 Adrenal insuff	iciency 10 Other MD1SCROT6
(select all that apply) 10 Hypotension 10 Extubation MI	D1SCREX6
MD1SCRBP6	






# FORM 15: MEDICATIONS






#### **TOLSURF MD2RANDN** ID2ACROS <sup>1</sup>O Yes <sup>0</sup>O No<sup>8</sup> O Unknown MD2CAFADM **CAFFEINE ADMINISTERED?** 15.2



#### 15.3. CONTINUOUS INFUSION PRESSOR(S) ADMINISTERED? 10 Yes 00 No8 0 Unknown (see MOP for definition, list all courses) MD2PRSADM



#### 15.4 VITAMIN A (administered to prevent BPD)

<sup>1</sup>O Yes <sup>0</sup>O No <sup>8</sup>O Unknown MD2VITA

15.4.a. Start Date: MD2VA\$TAR1 Stop Date: MD2VASTOP/1 MD2VAOG
----------------------------------------------------------------



F	ORM 16A	A: DIS	CHA	RGE REPOR	T
	Screening ID#	Secondary ID	Staff Initials	Randomization #	
	DE1 D	DE1AC	D <del>E1ST</del> ROS	DE RANDN	

#### 16A.1. DISCHARGED HOME FROM STUDY HOSPITAL:

**DE1HOME** 

16A.1.a. Was infant discharged home from study hospital? 1 O Yes 0 No


		Date of discharge home: DE1 HOMED / Year
	16A.1.a.ii. ∖	Weight at discharge home: PETHOMEWT grams
	1	Head circumference (to the nearest 0.5cm) at discharge home:
	16A.1.a.iv.	Respiratory status when discharged home: (select highest level of support)
		OO In room airDE1HOMEV2O Oxygen continuously1 O Mechanical ventilation w/trach3 O Oxygen intermittently
	16A.1.a.v. 16A.1.a.vi.	Oxygen saturation:  Which is a second of the control of the contro
	1	BPD Medications when discharged home: (select all that apply) DE1HOMEBD O Diuretics  10 Systemic steroids 10 NoneDE1HOMEBNO
	1	Bronchodilators 10 mnaled steroids 10 Unavailable DE1HOMEBU
JE'	<b>1HOMEBO</b>	Other DE1HOMEOS
DE	<b>HOMEMV</b>	O <sub>1</sub> Multivitamin type: <b>DE1HOMEMVS</b>
	TIONEN	Calviditivitatiiii type. DETITOMENIVO

#### 16A.2. <u>DISCHARGED TO OTHER HOSPITAL(OH):</u>

**DE1HOSP** 

16A.2.a. Was infant discharged to other hospital? 1 O Yes O No

16A.2.a.i. Date of discharge to other hospital: Day / Day Year
16A.2.a.ii. Weight at discharge to other hospital. Tgrams
16A.2.a.iii. Head circumference (to the nearest 0.5cm) at discharge to OH:
16A.2.a.iv. Respiratory status when discharged to other hospital:(select one)
O Off ventilator, off CPAP, off oxygen, off nasal cannula
10 On mechanical ventilation DE1HOSPV
20 On SiPAP, BiPAP or nasal prong ventilation
30 On nasal CPAP
4O On continuous nasal cannula
DETHOSPEO DETHOSPEPM
16A2.a.v. FiO2: DETHOSPEO DETHOSPLPM / Effective oxygen: FiO2: DETHOSPEO
16A.2.a.v.i. Oxygen Saturation HOSPO %
16A.2.a.vii. Last PCO2 prior to 36 week date: THO SPP (see MOP) O Unavailable





#### FORM 16B: HOSPITAL DISCHARGE BREATHING OUTCOME QUESTIONNAIRE



Screening ID#	Secondary ID	Staff Initials	Randomization #
DP1ID	DP1ACR	DP1\$ OS	TFID . DP1RANDN

This information to be collected from parent/guardian at time of discharge from study hospital and faxed to the DCC with other discharge forms.

Was interview conducted? **DP1INTCON** 

1 O Yes — Date questionnaire completed:



**DP1NOINTR** OO Child died 10 Unable to contact family 20 Family refused

16B.1. Information received from (list primary caregiver): (select one) DP1INF0FM

10 Mother 20 Father 30 Grandparent 40 Foster Parent

16B.2. How many people normally live in your home including your baby (for at least 6 months of the year)? (select one) DP1INH

> 102-3 204-6 **3**0 7 - 10 40 > 10

16B.2.a. Are there any children < 5 years of age (other than your baby) that live in the home?

**DP1CINH** None 10 1 - 2 30 6 - 8 203-5 40 > 8

16B.3. Do you have any pets? (select all that apply)

DP1PNONE DP1PCAT DP1PISH DP1PC DP1PISH DP1PC DP1PDOG DP1PFRY DP1PBDD DP1PDOG DP1PFRY DP1POTH

16B.4. Infant feeds: (select one)

**DP1FEEDS**30 Breast milk and formula 10 Breast milk only 50 Other

20 Formula only 40 No enteral feedings

16B.5. Will your child receive any care outside the home in the next year? DP10CARE 10 Yes 00 No 80 Unknown

16B.5.a. Who will provide care? (select all that apply) DP1CFRND DP1COTH 10 Friends 10 Other 10 Relatives 10 Daycare

16B.5.b. Will other children that are not siblings be present at outside care site? 10 Yes no No 80 Unknown DP10CLD

16B.6. Please describe the situation regarding smoking in your child's home: (select one)

16B.6.a. Which one of the following statements best describes the situation regarding smoking in your child's home? **DP1SMKSIT** 

1 O Smoking is allowed in any room in the home

2 O Smoking is limited to part of the house where the child will rarely go

**3** O Occasionally there is smoking inside the house (visitor, family member)

40 There is no smoking inside the house at all

50 Other

Draft



# FORM 16B: HOSPITAL DISCHARGE BREATHING OUTCOME QUESTIONNAIRE



Screening ID#	Secondary ID	Staff Initials	Randomization #
DP2ID.	DP2ACR	DP2ST OS	DP2RANDN

16B.6.b. Does either parent smoke? 1 Q Yes 00 No 80 Unknown DP2PSMK

> 16B.6.b.i. Estimated number of cigarettes per day: DP2PSMKPD 10 < 5 **9**0 5 - 10 3 O 11 - 20 4O > 1 pack/day 8O Unknown

16B.6.c. All together, how many people who live in the home smoke? **DP2PHSMK** 

00 None 101-2  $\frac{20}{2}$ 80 Unknown

16B.6.d. Will your child travel regularly (at least once a week) in a vehicle (car or truck) that someone smokes in, even when the child is not in the car? **DP2INCAR** 

10 Yes 00 No 80 Unknown

#### 16B.7. Please tell us what breathing and allergy problems run in the family.

16B.7.a. Biological parents - one or both: (select all that apply) 10 Asthma/recurrent lung infections 10 Medication allergies 10 Allergies (allergies/hayfever) 16B.7.b. Grandparents - one or both: (select all that apply) 10 Asthma/recurrent lung infections 10 Medication allergies 10 Allergies (allergies/hayfever) 16B.7.c. Siblings - one or both: (select all that apply) DP2SBOTH 10 Asthma/recurrent lung infections

10 Allergies (allergies/hayfever)

10 Medication allergies 10 Other

#### 16B.8. Please tell us more about your baby's background:

16B.8.a. Maternal education: (select one) DP2MATEDU

1 O Some education, High School not completed 3 O Some College 50 Graduate study

O High School graduate ▲ O College graduate 

♣O Unknown/Unavailable

16B.8.b. Paternal education: (select one) DP2PATEDU

1 O Some education, High School not completed 3 O Some College 5 O Graduate study

O High School graduate ▲ O College graduate 

♣O Unknown/Unavailable

16B.8.c. How will your child's health care be paid for? (select one) DP2PAY

10 Private Insurance 20 Medicaid/Public 30 No Insurance (self pay)



#### FORM 17: DEATH REPORT

Screening ID#	Secondary ID	Staff Initials	Randomization #
:DH1ID	PH1ACE		FID DH1RANDN

17.1. Did infant die?  O No O Unknown  Form complete. PI must still sign and
17.1.a. Date of Death:  DH1DOD  Month  Day  Year  date page 2.
17.1.b. How many days after dosing with study drug/sham did death occur? <b>DH1DOSING</b>
1 O ≤ 7 days — Enter death on Form 13A: Adverse Events, Q13A.2. and Form 21: Serious Adverse Events, Q21.1.
2 <sub>O</sub> > 7 days — Enter death on Form 13B: Adverse Events, Q13B.2. only. Do <u>NOT</u> enter this death on Form 21: Serious Adverse Events
17.2. Where did infant die? DH1WHERE  10 Study hospital 20 Home 30 Other hospital
17.3. Primary Cause of Death: (select one) DH1CDP  OO Sepsis 10 Respiratory Disease 70 Other - specify below:  DH1CDPOCM  (select one) DH1CDP  OO Sepsis 40 Pulmonary Hypertension 60 NEC 80 Unknown
17.4. Secondary Cause(s) of Death: (select all that apply)  1 DH1CDSSEP 10 Pulmonary Hypertension 10 Respiratory Disease 10 DH1CDSCA 10 Cardiopulmonary Arrest  10 DH1CDSUH 10 DH1CDSUH 10 DH1CDSUNK  11 DH1CDSUNK  12 DH1CDSUNK
17.5. Was life support withdrawn? DH1LIFESUP  1 <sub>O Yes</sub> 0 <sub>O No</sub> 8 Unknown



#### FORM 17: DEATH REPORT



### 17.6. What is the relationship of death to study drug/sham: (select one) 1 O Not related 2 O Unlikely 80 Unavailable/Unknown <sup>4</sup> O Probably related 30 Possibly related 5 Q Definitely related 17.6.a. Type of death: (review MOP instructions) **DH2TYPE** 10 Expected <sup>2</sup>O Unexpected <sup>1</sup>O Yes OO No OO Unknown 17.7. Was an autopsy performed? DH2AUTOP 17.7.a. Date of autopsy: Enter Cause of Death and Pulmonary autopsy findings below: 17.7.b. **DH2AUFIND** Principal Investigator Initials: DH2PII Principal Investigator Signature Form signed? <sup>1</sup>O Yes <sup>0</sup> O No **DH2PIS** Date of signature: Month Day

1 O DCC ONLY: Confirm PI signature and date DH2PISD



## FORM 18: PROTOCOL DEVIATIONS

Screening ID#	ID	Initials	Randomization #
PD1ID	PD1AC	PD1S ROS	IFID PDI RANDN

Fax Form 18: Protocol Deviations to the DCC as deviations occur. At least one Form 18, pgs 1 & 2, is required for each infant. The PI must sign and date page 2 of each Form 18 submitted. Each time there is a Protocol Deviation, complete pages 1 & 2. Enter the same PD Tracking # on both pages. For e.g. 1st PD Tracking # will be 01, 2nd PD Tracking # will be 02, etc. The same PD Tracking # cannot be used on more than one set of forms.

PD1PRODEV

PD Tracking #

D1TRACKN

18.1 HAS THERE BEEN A PROTOCOL DEVIATION(S)? 1 O Yes 0 O No 80 Unknown

	<u> </u>						
18.2	WHAT IS THE PROTOCOL DEVIATION(S): (select all that apply) PD10XC						
10	18.2.a. Failure to perform oxygen reduction challenge.						
	Describe:						
	PD10XCDESD						
10	18.2.b. iNO administration deviated from NO CLD protocol DURING iNO treatment.  PD1INODIJ (see Form 6, Q6.1.b.)						
	Document details of <u>HIGHEST</u> iNO dose administered DURING iNO treatment:						
	Highest concentration(during) Highest iNO start date (during) Highest iNO end date (during)						
	PD1 NODUS PD Year PD1 NODUSD Year Month Day Year						
10	10 18.2.c. Additional iNO administered AFTER completing iNO course per NO CLD Protocol. PD1INOAF (see Form 6, Q6.2b.)						
	Document details of <u>HIGHEST</u> additional iNO dose administered AFTER iNO treatment per NO CLD protocol.						
	Highest concentration(after) Highest iNO start date (after) Highest iNO end date (after)						
	PD1INOAFC PPM /INOAFSD PD 1/NOAFED Year Year						



<b>FORM 18:</b>	PRO	<b>TOC</b>	<u>OL DEVIATIONS</u>	5
	0	01-55		

OIXIVI IOI			<u> </u>	, i u O
Screening ID#	Secondary ID	Staff Initials	Randomization #	PD Tracking #
PD2ID	D2ACR PD	2STF	PD2RANDN PD	2TRACKN

SEE TOP OF PAGE 1 FOR DCC INSTRUCTIONS REGARDING THIS FORM. A PD TRACKING # IS REQUIRED ABOVE. FORM WILL BE NOT BE ACCEPTED BY THE DCC, IF THIS BOX IS BLANK.

10 18.2.d.	Deviation from Clinical Guidelines: (see MOP) PD2CLGDL Specify:
	PD2CLGPDCM
	Date of this Protocol Deviation: Month / PD2CLGDLD Year
1 O 18.2.e.	Other Protocol Deviation: PD2OTHPD  Specify:
	PD2OTHPDCM
	Date of this Protocol Deviation: Month / Day Year
Form	PD2PII  pal Investigator Signature  n signed: 10 Yes 00 No  PD2PIS  Date of signature:(mm/dd/yy)  C ONLY: Confirm PI signature and date PD2PISD



#### FORM 19: PROTOCOL VIOLATIONS

Screening ID#	Secondary ID	Staff Initials	Randomization #	Tracking #
PV1ID	PV1ACRO PV	OS ISTFII	PV1RANDN PV1	TRACKN

From Post Enrollment - Discharge: Fax Form 19: Protocol Violations to the DCC as violations occur. At least one Form 19, pgs 1 & 2, is required for each infant.

Enter the same number in the Tracking # box on pages 1 & 2 of this form. Note: tracking #s cannot be used on more than one form. i.e. one Tracking # per Form 19 (pgs 1 & 2)

For e.g. enter 01 for the first faxed form, 02 for the second, 03 for the third, etc.

#### 10 Yes 00 No 8 0 Unknown 19.1 HAS THERE BEEN A PROTOCOL VIOLATION(S)? **PV1PROV**

#### 19.2 WHAT IS THE NATURE OF THE PROTOCOL VIOLATION(S): (select all that apply) 10 19.2.a. Randomized but all Inclusion Criteria were NOT met. PV1INCNMET **Select Inclusion Criteria NOT met:** 10 Gestational age ≤ 28 weeks gestation PV1IAGE <sup>1</sup>O Between 7 and 14 days of age. PV1INT7T14 10 Infant intubated and mechanically ventilated between 7 - 14 days of life? PV1PLTRINO 10 Plan to treat with Inhaled Nitric Oxide? 19.2.a.i. Date of this Protocol Violation: 10 19.2.b. Randomized but Exclusion Criteria were present. PV1EXCPRES **Select Exclusion Criteria present:** O Serious congenital malformations or chromosomal abnormalities PV1SCMCA O Life expectancy < 7 seven days, starting at DOL 7 **PV1LEL** PV1CLINUNS 10 Clinically unstable 10 Bilateral Grade 4 intracranial hemorrhage PV1IVH 10 Less than 48 hrs from last dose of early surfactant **PV1TSUR** PV1EPTDATA 10 Unlikely to be able to collect primary endpoint data at 36 weeks. 19.2.b.i. Date of this Protocol Violation: 10 19.2.c. Consent not obtained in accordance with IRB guidelines. **PV1COIRBN** 19.2.c.i. Date of this Protocol Violation:



#### FORM 19: PROTOCOL VIOLATIONS

Screening ID#	Secondary ID	Staff Initials	Randomization #	PV Trooking #
PV2ID	PV2ACF	PV25 O\$	PV2RANDN	Tracking # PV2TRACKN

SEE TOP OF PAGE 1 FOR DCC INSTRUCTIONS REGARDING THIS FORM. A PV TRACKING # IS REQUIRED ABOVE. FORM WILL BE NOT BE ACCEPTED BY THE DCC, IF THIS BOX IS BLANK.

(Continuation of Q19.2)
1 O 19.2.d. Unblinding of study personnel.  PV2UNBLPR  Date of this Protocol Violation:  Day  Day  PV2UNBLPR  Day  PV2UNBLPR  Day  Pvau  Year
10 19.2.e. Study drug administration or dosing error.  PV2SDEROR Dose10#1 20#2 30#3 40#4 50#5  PV2SDERDS  Date of this Protocol Violation:  Month  Day  / PV2SDERORD
10 19.2.f. Withdrawal from study protocol for any reason.  PV2WDPRO  Date of this Protocol Violation:  Describe:  Describe:
PV2WDPROS
10 19.2.g. iNO not administered.  PV2INONGV  Date of this Protocol Violation:  Describe:  PV2INONGVD  Amonth  PV2INONGVD  Year
PV2INONGVS
10 19.2.h. Open label surfactant administered.pv20LSGVND PV20LSGVN Date of this Protocol Violation: Month Day Year
Principal Investigator Signature Form signed! O Yes OONO PV2PIS  1 PV2PISD  Principal Investigator Initials:  PV2PID  Date of signature:(mm/dd/yy)






#### FORM 20: EARLY TERMINATION / PERMANENT DISCONTINUATION OF MEDICATION

## **TOLSURF**

Screening ID#	Secondary ID	Staff Initials	Randomization #
EIDIDETT	ACROS ETD	STFIL	ETDRANDN

AN INFANT CAN EITHER PERMANENTLY DISCONTINUE STUDY DRUG/SHAM BUT REMAIN IN THE STUDY or TERMINATE EARLY BY DISCONTINUING ALL STUDY INVOLVEMENT

<sup>1</sup>O Yes <sup>0</sup>O No <sup>8</sup> O Unknown 20.1. Has infant discontinued study participation?



Principal Investigator Signature  Form signed: O Yes O No ETDI	ETDPII Principal Investigator Initials:
	10
<u>Date of signature</u>	
Month Day Year	1 O DCC ONLY: Confirm PI signature and date ETDPISD

# FORM 21: SERIOUS ADVERSE EVENTS

# TOLSURF

Screening ID#	Secondary ID	Staff Initials	Randomization #	SAE#
SE1ID	SE1ACR(	SE1S	SE1 RANDN	SE1SAEN



INSTRUCTIONS: Report all Serious Adverse Events that occurred since administration of study drug/sham. Enter a unique SAE# above (beginning with "001") and enter this SAE# in infant SAE log. Each infant can have multiple SAE Forms. If no SAEs, number this Form "SAE 001", and fill in "No" bubble that No SAE occurred.

		sted below occurred since pages 1 - 4. Pl must sign all 4			drug/sha	<b>m? 1</b> ○ Ye	s <b>0</b> 0 No	SE1SAE
ADVERSE EVENTS	REPORTED TO IRB	DATE OF EVENT (mm/dd/yy)	SEVERITY	RELATIONSHIP TO STUDY DRUG	ACTION TAKEN	OUTCOME	CAUSALITY	TYPE
21.1 SE1DEA 1 O Death -  That occurred ≤ 7 days after study drug dose/sham		SÉ1DEAD Enter Description on page 3,	SE1DEA	SE1DEAR	SEIDEA	A SE1DEAC	SE1DEAC	SE1DEA
21.2 SE1RES 10 Severe Respiratory Decompensation (defined as RSS > 5 above baseline for > 24 hrs) -	O Yes 1 O No 0	SETRESD/ Enter Description on page 3,	SE1RESS Q21.2.a.		SE1RES		SE1RESC	
That occurred ≤ 4 hours after study drug dose/sham	SE1RES	1		SE1RESR		SE1RESC		SE1REST
21.3 SE1CPR 1 O Severe Cardiopul- monary Decompensation requiring CPR with chest compressions and	O Yes1 O No 0	SF1CPRD/ Enter Description on page 3,	SE   CPR	<b>s</b>	SE1CPR	<b>A</b>	SE1CPRC	
cardiac medication -  That occurred ≤ 4 hours after study drug dose/sham	SE1CPR	RI		SE1CPRR		SE1CPRO		SE1CPR
	al Investig	I must be faxed to DCC ator must sign and date	1=Mild 2=Moderate 3=Severe 4=Life-threa tening 8=Unavailable Unknown	4=Probably 5=Definitely related 8=Unavailable/	1=Not applicable 2=Study Drug discontinued. 3=Standard Care 8=Unavailabl e/ Unknown		1=Not related to study drug 2=Concomitant med 3=Underlying condition 4=Study drug dosing 5=Unknown 6=Other	1=Expected 2=Unexpected

# FORM 21: SERIOUS ADVERSE EVENTS TOLSURF

Screening ID#	Secondary ID	Staff Initials	Randomization #	SAE#
SE2ID	SE2ACR	E2ST S	SE2RANDN	SE2SAEN



SERIOUS ADVERSE EVENTS	REPORTED TO IRB	(mm/dd/yy)	SEVERITY	RELATIONSHIP TO STUDY DRUG	ACTION TAKEN	OUTCOME	CAUSALITY	TYPE of EVENT
21.4 <b>SE2PIE</b> 1 O Severe PIE That occurred < 24 hours after study drug dose/sham	SE2PIEI 10 Yes 00 No	SE2PIED / Enter Description on page 4, Q	\$E2PIE\$ 21.5.a.	SE2PIER	SE2PIE/	SE2PIEO	SE2PIEC	SE2PIET
21.5 <b>SE2PUL</b> 1 O Severe Pulmonary Hemorrhage  That occcurred ≤ 24 hours	<b>0</b> 0 No		SE2PULS	SE2PULR	_	SE2PULO		SE2PULT
after study drug dose/sham		Enter Description on page 3, Q	21.4.a.		E2PULA		SE2PULC	
21.6 SE2PNE  1 O Pneumothorax requiring Chest Tube  That occurred ≤ 24 hours after study drug dose/sham	10 Yes 00 No	Enter Description on page 4. Q	E2PNES 21.6.a.	SE2PNER	SE2PNE	SE2PNEO	SE2PNEC	SE2PNET
21.7 SE2UNXAE  10 Unexpected Adverse Event That is related to and	10 Yes 00 No	SE2UNXAED / / / / / / / / / / / / / / / / / / /		SE2UNXAE		SE2UNX		2UNXAET
accurred within 7 days of	SE2UNX	Enter Description on page 4, Q	21.7.a. SE2UNX	AES	SE2UNX	AEA	SE2UNXAE	c .

# FORM 21: SERIOUS ADVERSE EVENTS

Screening ID#	Secondary ID	Staff Initials	Randomization #	SAE#
SE3ID	SE3ACRO	3STF S	SE3RANDN	SE3SAEN



#### **Narrative record of Serious Adverse Event**

Please briefly describe SAE. Also copy physician's progress notes from the incident and fax with cover sheet to UCSF/CC, attn. Roberta Ballard at 415-514-8150.

21.1.a - Death - Description:

#### **SE3DEACM**

21.2.a - Severe Respiratory Decompensation - Description:

#### **SE3RESCM**

21.3.a - Severe Cardiopulmonaryr Decompensation requiring CPR with chest compressions and cardiac meds: Description:

#### **SE3CPRCM**

21.4.a - Severe Pulmonary Hemorrhage - Description:

#### **SE3PULCM**



All 4 pages of Form 21 must be faxed to DCC and Principal Investigator must sign and date Form 21, page 4.

# FORM 21: SERIOUS ADVERSE EVENTS TOLSURF

Screening ID#	Secondary ID	Staff Initials	Randomization #	SAE#
SE4ID	SE4ACRO	4STFII	SE4RANDN	SE4SAEN

	raft	
	□	▗▞▘
1		L <sup>™</sup> ■■
l		

Narrative record of Serious Adverse Event Please briefly describe SAE. Also copy physician's progress notes from the incident and fax with cover sheet to UCSF/CC, attn. Roberta Ballard at 415-514-8150.
21.5.a - Severe PIE - Description:
SE4PIECMT
21.6.a - Pneumothorax with chest tube - Description:
SE4PNECMT
21.7.a - Unexpected Adverse Event related to and occurred within 7 days of study drug dose/sham - Description:
SE4UXAECMT

I have reviewed all 4 pages of Form 21 and i	it is accurate to the best of my knowledge.
Principal Investigator Signature  Form signed? <sup>1</sup> O Yes <sup>0</sup> O No SE4PIS	Principal Investigator Initials:    J   SE4PII



1 O DCC ONLY: Confirm PI signature and date **SE4PISD** 



## FORM 23: BREATHING OUTCOMES INTERVAL QUESTIONNAIRE


# Screening ID # Secondary | Staff | Randomization # | DP.8ID | DP3\$TFID | DP3\$

# **TOLSURF**

23.1. Corrected age at current interview: DP3VISIT

3 O 3 Months 6 O 6 Months 9 O 9 Months 2 O 12 Months 18 O 18 Months

History of last interview						
	<b>DP3LASTD</b> Date of last interview:	Month	Day /	Year		
23.3. Which interview was the last one conducted? DP3LASTAGE						
	O Discharge O 3 Mo	nths $0_6^6$	Months	O <sub>9</sub> 9 Months	Q <sub>12</sub> 2 Months	988 Months



23.5. Information on this form received from: (select one) DP3FROM

10 Mother 20 Father 30 Grandparent 40 Foster Parent 50 Other



# FORM 23: BREATHING OUTCOMES INTERVAL QUESTIONNAIRE



# TOI SURF

Screening ID#	Secondary ID	Staff Initials	Randomization #
DP4ID DP4	DP4 IACROS	STFID	DP4RAND

<u> </u>	DP4VISIT PF4AGROS   P1 PCAGROS
Cor	rected age 3 0 3 Months 6 0 6 Months 9 0 9 Months 120 12 Months 180 18 Months
23.6.	Since discharge (or last interview), has your child had a cough without a cold?  1 O Yes 00 No DP4COUGH
	23.6.a. How often do you notice a cough without a cold? (select one) DP4COUGHOF  1 O Every day  2 O Not every day but more than once per week  3 O Once a week  4 O Not every week
	<ul> <li>23.6.b. When does your child have this cough without a cold: (select one) DP4COUGHWH</li> <li>1 O More often during the day</li> <li>2 O The same amount whether it is day or night</li> <li>3 O More often at night</li> </ul>
23.7.	Since discharge (or last interview), has a medical person (nurse or doctor) told you he/she heard wheezing when listening to your child's chest?  10 Yes 00 No
	23.7.a. When has a medical person heard wheezing in your child's chest? (select one)  1 O Only when my child has had a cold  2 O Only when my child has not had a cold  3 O Both when my child has had a cold and without a cold
23.8.	Since discharge (or last interview), has your child been treated in the Emergency Department or by another doctor in the office or clinic because of a breathing problem or a change in his/her breathing? DP4ER  10 Yes 00 No
	23.8.a. How many times was your child treated in the Emergency Department, office or clinic?  1 ○ ≤ 2 2 ○ 3 - 5 3 ○ 6 - 10 4 ○ > 10 DP4ERN
23.9.	Since discharge (or last interview), has your child been admitted to the hospital overnight?  10 Yes    DP4HOSP
	23.9.a. How many times was your child admitted to the hospital overnight?
	23.9.b. How many times was this because of a breathing problem or a change in his/her breathing?  DP4HOSPBRN




# FORM 23: BREATHING OUTCOMES INTERVAL QUESTIONNAIRE



TULSUKF \_\_DP5VISIT\_\_\_

Corrected age:30 3 Months 60 6 Months 90 9 Months 120 12 Months 180 18 Months

23.10. Is your child currently on oxygen or a breathing machine (ventilator) at home?



23.11. Since discharge (or last interview), has your child been diagnosed with a respiratory syncytial virus (RSV) infection? **DP5RSV** 

10 Yes **0**0 No

23.12. Which of these medications has your child been prescribed (at home or in the hospital) since discharge (or last interview)? *(select all that apply)* 

A)10 DP5INBRON Inhaled bronchodilators

- 1 D) O Systemic steroids DP5SYSTER
- B)10 Inhaled steroids DP5INSTER
- 1 E) O Pulmonary vasodilators **DP5PULVAS**
- C)10 Diuretics DP5DIUR
- **1** F) O None of the above **DP5NOTA**

See Medication list on last page

23.12.1. Has your child taken any vitamins or supplements that contain Vitamin D (since discharge or last interview)?

DP5VITD

1 O Yes 0 O No

See Medication list on last page



#### FORM 23: BREATHING OUTCOMES INTERVAL OUESTIONNAIRE

Secondary Staff Initials		Randomization #		
P6ACRC	\$	DP6RANDN		

## **TOLSURF**

Screening ID# DP6STFID L

Corrected age:30 3 Months 60 6 Months 90 9 Months 20 12 Months 80 18 Months 23.13. How many people normally live in your home including your baby (for at least 6 months

of the year)? (select one) **DP6HOMENUM** 

10 2 - 3 2 0 4 - 6

**3** O 7 - 10

4 O > 10

23.13.a. Are there any children < 5 years of age (other than your baby) that live in the home?

None

101-2

**9** 0 3 - 5

30 6 - 8

**4** 0 > 8

23.14. Do you currently have any pets? (select all that apply)

DP6PCAT

DP6PCAT

O None D Dog 10 Cat 10 Other furry animals 10 Fish 10 Birds 10 Other DP6POTH DP6PDOG DP6PFRY **DP6PBIRD** 

#### Complete Qs23.15.a. & 23.15.b. below, only if this is a 6 or a 12 Months Interview

23.15.a. What type of milk does your child drink? (select one) DP6MILKTYP

10 Breast milk only

3 O Breast milk and formula

50 Other

20 Formula only

4 O No enteral feedings

23.15.b. Was breast milk discontinued since last interview? **DP6BMKDS** 

10 Yes **0**0 No

23.15.b.i. How old (in months) was the child when breast milDP6BMKMO was discontinued? (approximate corrected age in months months)

#### Complete Q23.16 below, only if this is an 18 Month Interview

23.16. Is child currently still taking some breast milk? DP6BMK18 10 Yes **0**0 No

23.16.a. Was breast milk discontinued since last interview? DP6BMKDS18

10 Yes **0**0 No

23.16.a.i. How old (in months) was the child when breast milk was discontinued? (approximate corrected age in months) DP6BMKMO18

l I	months

Draft



# FORM 23: BREATHING OUTCOMES INTERVAL OUESTIONNAIRE

Screening ID#	Secondary ID	Staff Initials	Randomization #
DP7ID D	P7ACRO	OP7STF S	DP7RANDN

Corrected age: 30 3 Months 60 6 Months 90 9 Months 120 12 Months 180 18 Months

23.17. Does your child receive any care outside the home? DP7CARE

1 O Yes 0 O No

17 a Who provides care? (select all that apply)

23.17.a. Who provides care? (select all that apply)

DP7CAREWRE
10 Relatives 10 Daycare 10 Friends 10 Other

DP7CAREWDC

23.17.b. Are other children that are not siblings present at outside care site?

DP7CAREWDC

DP7CAREOTH

- 23.18. Please describe the situation regarding smoking in your child's home.
  - 23.18.a. Which one of the following statements best describes the situation regarding smoking in your child's home? (select one) **DP7SMKHOM** 
    - 1 O Smoking is allowed in any room in the home
    - 2 O Smoking is limited to part of the house where the child will rarely go
    - **3** O Occasionally there is smoking inside the house (visitor, family member)
    - 4 O There is no smoking inside the house at all
    - 5 O Other
  - 23.18.b. Does either parent smoke? 10 Yes 00 No 20 Don't know

23.18.b.i. Estimate number of cigarettes per day: **DP7SMKNCIG** 

10 < 5 2 0 5 - 10 3 0 11 - 20 4 0 > 1 pack/day 8 0 Unknown

23.18.c. Altogether, how many people who live in the home smoke? **DP7SMKNUM** 


**0** O None **1** O 1 - 2 **2** O > 2

23.18.d. Does your child travel regularly (at least once a week) in a vehicle (car or truck) that someone smokes in, even when the child is not in the car? **DP7SMKCAR** 

1 O Yes () O No



#### FORM 23: BREATHING OUTCOMES INTERVAL QUESTIONNAIRE



Corrected age: ● 18 Months 18

23.19. Has your child ever had hay fever or another condition that makes his/her nose or eyes runny, stuffy or itchy without a cold? **DP8HAYFVR** 

1 O Yes () O No

23.20. Has your child ever been allergic to any food? (these are reactions that include rash and swelling, not vomiting or diarrhea) DP8ALLRGFD

1 O Yes () O No

23.21. Has your child ever been allergic to any medicine (these are reactions that include rash and swelling, not vomiting or diarrhea) DP8ALLRGMD

1 O Yes **()**O No

23.22. Has your child ever had eczema diagnosed by a doctor (allergic skin rash)? DP8ECZEMA

1 O Yes () O No

23.23. Has your child been diagnosed with asthma by a doctor? **DP8ASTHMA** 

1 O Yes 0 O No

### TOLSURF FORM 23: BREATHING OUTCOMES INTERVAL QUESTIONNAIRE

#### **MEDICATIONS REFERENCE SHEET**

#### **INTERVIEWER NOTE:**

#### BELOW ARE EXAMPLES OF THE MEDICATIONS LISTED ON Q23.12:

- A) INHALED BRONCHODILATORS
  - 1) Albuterol (Ventolin)
  - 2) levoalbuterol (Xopenex)
  - 3) ipratropium bromide (Atrovent)
- B) INHALED STEROIDS
  - 1) beclomethasone (Beclovent, Qvar, and Vanceril)
  - 2) budesonide (Pulmicort)
  - 3) flunisolide (Aerobid)
  - 4) fluticasone (Flovent)
  - 5) triamcinolone (Azmacort)
- C) DIURETICS
  - 1) furosemide (Lasix)
  - 2) chlorothiazide or hydrohlorothiazide (Diuril or Hydrodiuril)
  - 3) aldactone

- D) SYSTEMIC STEROIDS
  - 1) cortisone
  - 2) dexamethasone
  - 3) prednisone
  - 4) prednisolone
  - 5) methylprednisolone
- E) PULMONARY VASODILATORS
  - 1) sildenafil (Revatio)
  - 2) tadalafil (Adcirca)
  - 3) bosentan (Tracleer)
  - 4) ambrisentan (Myogen)
  - 5) inhaled iloprost (Ventavis)
  - 6) beraprost
  - 7) trepopostinil
  - 8) epoprostenol (Flolan)
  - 9) inhaled nitric oxide

#### **INTERVIEWER NOTE:**

#### BELOW ARE EXAMPLES OF THE MEDICATIONS REFERRED TO ON Q23.13:

#### VITAMINS OR VITAMIN SUPPLEMENTS

- 1) Polyvisol with/without iron
- 2) Trivisol with/without iron
- 3) D-visol
- 4) Multivitamin drops
- 5) Children's Complete chewable vitamins/multivitamin, with/without iron and with/without calcium:

Centrum

Flinstones

**Bugs Bunny** 

Pokeman

Scooby Doo


6) Lil' Critters

**TOLSURFMedication References** v1.0, 08/16/2010




# FORM 24: NEURODEVELOPMENTAL FOLLOW-UP EXAM





Corrected age at current exam: 12 0 12 Months 24 0 24 Months ND1VISIT

24.1. Details of this Neurodevelopmental Exam:



24.1.b. Where was child evaluated? (select one)

ND1EVAI	∠ ○ Over th	w-up clinic e telephone <b>–</b> ital as in-patie	24.1.b.i. Reason	ND1TELREAS  24.1.b.i. Reason evaluated over the phone: (select one)  1 O Moved out of area of follow-up clinic site  2 O Could not schedule follow-up clinic visit		
	4 O Other	Specify: NI	D1EVALSP			
24	.1.c. Date of t	his interview:	Month Day	ND1EVA	LD	
24.2. Infor	ND1REL mation receive	ed from: (select	t one)			
	1 O Mother	2 O Father	3 Grandparent	<b>4</b> ○ Foster Parent	5 ○ Other	



# FORM 24: NEURODEVELOPMENTAL FOLLOW-UP EXAM

$T \cap I$		
		·⊬⊢
1 ( ) (	LSU	

Screening ID#	Secondary ID	Staff Initials	Randomization #
ND2ID	ND2AC	SON STATE	ND2RANDN

	NUZSTPIU
Corrected age at current exam: 12	○ 12 Months 24 ○ 24 Months ND2VISIT
24.3. Family/Social history at time of assessment.	
24.3.a. Living arrangement: (select one) ND2L  1 ○ One parent  2 ○ Two parents  3 ○ Foster home  4 ○ Other → Describe: ND2LVDI	
24.3.b. Primary Language spoken in the home:	(select one) ND2LANG
1 ○ English spoken as first language	
2 O English spoken as second language.	0
<ul><li>3 ○ English spoken very little or not at all.</li><li>8 ○ Unknown</li></ul>	Specify 1st language: ND2ENGNOT
<ul> <li>24.3.c. Maternal education: (select one) ND2M</li> <li>1 O Some education, high school not comp</li> <li>2 O High school graduate</li> <li>3 O Some college</li> <li>24.3.d. Maternal employment: (select one) ND2</li> <li>1 O Employed as: Specify: ND2MAT</li> <li>2 O Full time homemaker</li> <li>3 O Student</li> <li>4 O Unemployed</li> </ul>	4 O College graduate 5 O Graduate study 8 O Unknown/Unavailable
8 ○ Unknown	
24.4. Medical history at time of assessment.	
<ul> <li>24.4.a. Since initial hospitalization or last follow-diagnoses or surgeries? (select all that a ND2GAST Gastrostomy tube placement</li> <li>10 Ventriculoperitoneal shunt placement</li> <li>10 Seizure disorder requiring treatment</li> <li>10 Failure to thrive ND2FAIL</li> </ul>	<ul> <li>-up exam, has child received any of the following apply)</li> <li>1 O Tympanostomy tube placement</li> <li>1 O Eye surgery ND2EYE</li> <li>1 O PDA ligation or other closure of PDA</li> <li>1 O No diagnoses, or surgeries received since initial hospitalization or last follow-up exam ND2NODI</li> </ul>



### FORM 24: NEURODEVELOPMENTAL

DLLOW		XAM
 Secondary	Staff	5



Screening ID#	Secondary ID	Staff Initials	Randomization #
ND3ID	ND3ACR	OS N <del>D3ST</del> I	ND3RANDN

120 12 Months 24 0 24 Months ND3VISIT Corrected age at current exam:

24.4.b. How many times has child been hospitalized for non-respiratory illness or surgery? (total hospitalizations, including those identified on Question 24.4.a.)

> Total number of hospitalizations: ND3HOSN None 10 N/A (infant still in hospital) ND3HOSNONE

#### ANSWER QUESTION 24.4.c. AT 12 MONTHS and 24 MONTHS EXAM

- 24.4.c. Is child currently taking any of the following medications for a chronic medical condition? (select all that apply)
  - 10 Anti-reflux medications ND3ANTIRE
  - 10 Prokinetics ND3PROK
  - 10 Anti-epileptics ND3ANTIEP
  - 10 Other Specify: ND3OTHSP
  - 10 Not taking any medications listed above

ND3NOT

See Medication list on last page

#### **ANSWER QUESTION 24.4.d. AT 24 MONTHS EXAM**

- 24.4.d.i. Which of the medications below has child been prescribed (at home or in the hospital) since the 12 Months interview? (select all that apply)
  - ND3INBRON 1 A) O Inhaled bronchodilators
  - 1 B) O Inhaled steroids
  - 1 C) O Diuretics ND3DIUR
  - 1 D) Systemic steroids ND3SYSTER
- 1E) Pulmonary vasodilators ND3PULVAS
- ND3VITD Vitamins/supplements containing Vit.D
- O None of the above ND3NOTA

See Medication list (A - F) on last page

- 24.4.d.ii. Has your child ever had hay fever or another condition that makes his/her 10 Yes 10 No nose or eyes runny, stuffy or itchy without a cold? ND3HAYFVR
- 24.4.d.iii. Has your child ever been allergic to any food? (these are reactions that 10 Yes 00 No include rash and swelling, not vomiting or diarrhea) ND3ALLRGFD
- 24.4.d.iv. Has your child ever been allergic to any medicine? (these are reactions 10 Yes 00 No that include rash and swelling, not vomiting or diarrhea) ND3ALLRGMD
- 24.4.d.v. Has your child ever had eczema diagnosed by a doctor? (allergic skin rash) 10 Yes 00 No
- 24.4.d.vi. Has your child been diagnosed with asthma by a doctor? ND3ASTHMA 10 Yes 00 No

Draft



## FORM 24: N

NEU	RODI	_VLL	LOPIM	IEN I	AL
FOL	LOW-	UP E	XAM		

٦	$\Gamma I$	$\cap$	ı	C	ı		Г
		U	L	S	U	R	r


Screening ID#	Secondary ID	Staff Initials	Randomization #
ND4ID I	ND4ACRO	OS D <del>4STF</del>	ND4RANDN

Corrected age at current exam: 12 \cap 12 Months 24 \cap 24 Months ND4VISIT

24.4.e. Milestones:	ND4SIŢ	1 <sub>O Yes</sub> 0 <sub>O No</sub>	
24.4.e.i. Is child able to sit alor	ne without support?	Yes	)
24.4.e.i.a. Corrected age support:	at which child sat alc	one without	ND4AGESIT months
24.4.e.ii. Is child able to walk i	independently? 10 Ye	es <mark>0</mark> 0 No	
24.4.e.ii.a. Corrected age independently			<b>GEWALK</b> onths
24.5. Child's growth parameters at	time of assessment:		
ND4WEIGHT 24.5.a. Weight (kg):	24.5.b. Rec	ND4LENG umbent Length (	TH cm):
24.5.c. Head circumference (ND4HE	cm):		
24.6. Child's vision at time of asses	sment:		
24.6.a. Visual function: <i>(selection of the land)</i> O Normal 2 ○ Unilate	ct one) ND4VISFUN eral blindness 30 Bila	NC ateral blindness	40 Prescription glasses
24.6.b. Visual problems at tim	ne of assessment: (se	lect one) ND4V	ISPROB
1 ○ None	5 ○ Cataracts		
<b>2</b> ○ Strasbismus	<mark>6</mark> ○ Glaucoma		
3 Cortical blindness	<b>7</b> ○ Retinal detachme	nt	
4 Optic atrophy	8 ○ Other Specify:	ND4VIOTH	SP
24.7. Child's hearing: 24.7.a. Hearing function: (see	lect one) ND4HEAF	<b>t</b>	
↑ ○ Normal		NDALINIA	MD
2 O Unilateral hearing I			
3 ○ Bilateral hearing lo	ss — 24.7.a.ii. F	Requires amplific	ation?1○ Yes 0 ○ No



#### FORM 24: NEURODEVELOPMENTAL FOLLOW-UP EXAM



Corrected age at current exam:


O 12 Months

O 24 Months


24.8. Modified Gross Motor Function Test:

#### ND5GMFDONE

24.8.1. Was the Modified Gross Motor Function Test performed?



ND5VISIT



ND5CP 24.9. Has a physician diagnosed this child with cerebral palsy? O Yes ○ No ○ Unknown ND5CPTYPE 24.9.1. Gerebral palsy is characterized by: (select one) 4 ○ Diplegia○ Hemiplegia Quadriplegia O Other




# FORM 24: NEURODEVELOPMENTAL FOLLOW-UP EXAM

Screening ID#	Secondary ID	Staff Initials	Randomization #
ND6ID	ND6ACR	DS D <del>6STF</del>	ND6RANDN

Corrected age at current exam: 0 24 Months ND6VISIT

### DO NOT PERFORM THE BAYLEY INFANT DEVELOPMENT III TEST IF THIS

NEURODEVELOPMENTAL EXAM IS COMPLETED OVER THE TELEPHONE.
24.10. Bayley Scale of Infant Development III: ND6BSIDONE 24.10.1. Did child perform the Bayley Infant Development III test? 1 Yes No
24.10.1.a. Reason(s) test not done: (select all that apply)  1 Visual impairment ND6VISIMP 1 Hearing impairment ND6HEARIMP 1 Child did not cooperate with several exam attempts 1 Other Specify: ND6OTHSP THIS PAGE IS COMPLETE, GO TO NEXT PAGE
24.10.2. Was this test administered in English? 1 O Yes No
24.10.2.a. Was an interpreter used? <sup>1</sup> O Yes <sup>0</sup> O No
24.10.3. Date test done: Month / Day / ND6BSIDD
24.10.4. Bayley Scoring:  24.10.4.a. Cognitive Composite score:
ND6LCS  24.10.4.b. Language Composite score:  ND6RLSS  24.10.4.b.i. Receptive Language scaled score:
24.10.4.b.ii. Expressive Language scaled score:
24.10.4.c. Motor Composite score:  ND6MCS  ND6GMSS  24.10.4.c.i. Gross Motor scaled score:
ND6FMSS 24.10.3.c.ii. Fine Motor scaled score:
24.10.5. BSID III Examiner signature:
ND6SIG 24.10.5.a. Is this page signed? 1 Yes ONO Date signed: ND6SIGD / Year



# FORM 24: NEURODEVELOPMENTAL FOLLOW-UP EXAM

Screening ID#	Secondary ID	Staff Initials	Randomization #
ND7ID I	D7ACR	DS D <del>7STF</del>	ND7RANDN

#### Corrected age at current exam<sup>24</sup> 24 Months ND7VISIT

24.11. M-CHAT- If parent unable to completed at the Clinic Follow-up Visit, please complete by telephone.

24.11.1. Date if completed by parent at Clinic Follow-up visit:	24.11.1.a. Date if completed over the telephone:
ND7/CLIND / 10 Not done	NOTPHOMED ON Not done
Month Day Year ND7CLINNO	Month Day YearND7PHONNO

Please fill out the following questions about how your child usually is. Please try to answer every question. If the behavior is rare (e.g., you've only seen it once or twice), please answer as if the child does not do it.

QUESTIONS	YES		No answer
24.11.2. Does your child enjoy being swung, bounced on your knee, etc.? ND7SWUNG	10	<u>0</u> 0	<b>8</b> 0
24.11.3. Does your child take an interest in other children?  ND70THCHLD	10	<u>0</u> 0	<b>&amp;</b> ○
24.11.4. Does your child like climbing on things, such as up stairs?  ND7CLIMB	<b>1</b> 0	<b>0</b> 0	<b>%</b>
24.11.5. Does your child enjoy playing peek-a-boo/hide-and-seek?	<b>1</b> 0	00	<b>8</b> 0
24.11.6. Does your child ever pretend, for example, to talk on the phone or take care of dolls, or pretend other things?  ND7PRETEND	10	<b>0</b> 0	<b>8</b> 0
24.11.7. Does your child ever use his/her index finger to point, to ask for something ND7ASK	<b>1</b> 0	00	<b>8</b> 0
24.11.8. Does your child ever use his/her index finger to point, to indicate interest in something?	<b>1</b> 0	<u>0</u> 0	<b>8</b> 0
24.11.9. Can your child play properly with small toys (e.g., cars or bricks) without just mouthing, fiddling, or dropping them?	10	<b>0</b> 0	<b>8</b> 0
24.11.10. Does your child ever bring objects over to you (parent) to show you somethings HOW	<b>1</b> 0	<b>0</b> 0	<b>8</b> 0
24.11.11. Does your child look you in the eye for more than a second or two?	<b>1</b> 0	00	<b>8</b> 0
24.11.12. Does your child ever seem oversensitive to noise? (e.g., plugging ears ND7NOISE	10	<b>0</b> 0	<b>8</b> 0
24.11.13. Does your child smile in response to your face or your smile?	4 -	<b>0</b> 0	<b>8</b> O
24.11.14. Does your child imitate you? (e.g., if you make a face, will your child initate it?)	10	<u>0</u> 0	<b>8</b> 0
24.11.15. Does your child respond to his/her name when you call?	4	<mark>0</mark> 0	<b>8</b> 0
24.11.16. If you point at a toy across the room, does your child look at it?	_	<mark>0</mark> 0	<b>8</b> O
24.11.17. Does your child walk?	<b>1</b> 0	<b>0</b> 0	<b>8</b> ⊙
24.11.18. Does your child look at things you are looking at?	10	<b>0</b> 0	<b>&amp;</b> O
24.11.19. Does your child make unusual finger movements near his/her face? ND7FINGER	10	<b>0</b> 0	<b>8</b> 0
24.11.20. Does your child try to attract your attention to his/her own activity?ND7ATTRACT	10	<b>0</b> 0	<b>8</b> O
24.11.21. Have you ever wondered if your child is deaf?  ND7DEAF	10	<b>0</b> 0	<b>8</b> 0
24.11.22. Does your child understand what people say? ND7SAY	10	<b>0</b> 0	<b>8</b> 0
24.11.23. Does your child sometimes stare at nothing or wander with no purpos ND7STARE	<b>1</b> 0	<b>0</b> 0	<b>8</b> 0
24.11.24. Does your child look at your face to check your reaction when faced with something unfamiliar?  ND7CHECK	<b>1</b> 0	00	<b>8</b> 0





### FORM 25: COMMENTS FORM - OPTIONAL

Screening ID#	Secondary ID	Staff Initials	Randomization #
CM11D	CM1ACR	OS M1ST	CM1RANDN

If needed, use this form to document additional pertinent information regarding this infant.

Question #	Comments

CM1PGN

of

TOLSURF [CM1] v1.0, 02/21/11

